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ABSTRACT OF DISSERTATION

RENAL HUMORAL, GENETIC AND GENOMIC MECHANISMS UNDERLYING
HERTIABLE HYPERTENSION

In spite of significant progress in our knowledge of mechanisms that control
blood pressure, our understanding of the pathogenesis of hypertension, its
genetics, and population efforts to control blood pressure, hypertension remains
the leading risk factor for mortality worldwide. It’s estimated that 1 out of every 3
adults has hypertension. Hypertension is a major risk factor for cardiovascular
disease and stroke, and is considered a primary or contributing cause of death to
more than 2.4 million US deaths each year. Although spontaneous hypertension
has been the subject of substantial research, many critical questions remain
unanswered.
To investigate mechanisms underlying spontaneous hypertension, a unique
rodent breeding approach was used to isolate nuclear and mitochondrial genes
contributing to the disease. By diluting the nuclear genome of the Spontaneously
Hypertensive Rat on a normotensive Brown Norway background while
maintaining the SHR mitochondrial genome, I investigated both intrinsic and
extrinsic mechanisms of the kidney and its relationship to hypertension. Chapter
2 documents the dominance of the hypertensive phenotype in our rodent colony,
despite the dilution of the nuclear genome of the SHR. Chapter 3 presents data
indicating that the renin-angiotensin system, particularly the location and
abundance of the AT1 receptor may play an important role in the manifestation of
spontaneous hypertension. Chapter 4 presents that rats in our rodent colony
exhibited normal pressure-natriuresis and kidney function; however, hypertensive
rats had a reduced ability to sense orally ingested sodium chloride, thus
necessitating chronic elevations of arterial pressure in order to maintain sodium
balance. This chronic pressure-natriuresis relationship shifts the renal function
curve to the right, thus sustaining elevated blood pressure. Chapter 5 presents
data that genes important for oxidative phosphorylation may play a critical role in
the development of hypertension. Both nuclear and mitochondrial oxidative

phosphorylation genes were downregulated in hypertensive rats compared with
normotensive rats. Data presented in every chapter highlights the importance of
the kidney in the pathogenesis of hypertension. Humoral, genetic and genomic
mechanisms of the kidney appear to play a dominant role in the development
and maintenance of the disease.
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To Mom and Dad

“Research is what I’m doing when I don’t know what I’m doing”- Wernher von
Braun

“There is nothing like looking, if you want to find something. You certainly usually
find something, if you look, but it is not always quite the something you were
after.”- J.R.R. Tolkien, The Hobbit
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CHAPTER 1
KIDNEY, LONG-TERM CONTROL OF ARTERIAL PRESSURE AND
HYPERTENSION
Jason Andrieu Collett

Abbreviations used: BP, blood pressure; TPR, total peripheral resistance; CO,
cardiac output; RAS, Renin-Angiotensin System, ECFV, extracellular fluid
volume; AVP, arginine vasopressin; MD, macula densa’ cTAL, cortical thick
ascending limb; JGA, juxtaglomerular apparatus; GFR, glomerular filtration rate;
Ang II, angiotensin II; RPP, renal perfusion pressure; RVLM, rostral ventrolateral
medulla; NTS, nucleus of the solitary tract; RSNA, renal sympathetic nerve
activity; RBF, renal blood flow; SNA, sympathetic nerve activity; Ang,
angiotensin; ACE, angiotensin-converting enzyme; AT1(r), angiotensin II type 1
receptor; AT2(r), angiotensin II type 2 receptor; CVLM, caudal ventrolateral
medulla; ENaC, epithelial sodium channel; SFO, subfornical organ; OVLT,
organum vasculosum of the lamina terminalis; MnPO, median preoptic nucleus;
PVN, paraventricular nucleus of the hypothalamus; ADH, antidiuretic hormone;
CVO, circumventricular organs; SON, supraoptic nucleus of the hypothalamus;
ICV, intraerebroentricular; AP, area postrema; VSMC, vascular smooth muscle
cells; CNS, central nervous system; ARB, angiotensin II receptor blocker; SHR,
Spontaneously Hypertensive Rat; IV, intravenously; QTL, quantitative trait loci;
CNV, copy number variant; OXPHOS, oxidative phosphorylation system; ROS,
reactive oxygen species; nDNA, nuclear DNA; mtDNA, mitochondrial DNA;
rRNA, ribosomal RNA; tRNA, transfer RNA; SNPs, single nucleotide
polymorphisms; ETC, electron transport chain; HNF-1α, hepatocyte nuclear
factor-1alpha; PGC-1α, Peroxisome proliferator-activated receptor gamma
coactivator 1 alpha; NRF, nuclear respiration factor(s); Tfam, transcription factor
A mitochondria; NO, nitric oxide; SOD, superoxide dismutase; NT, normotensive;
HT, hypertensive;

Keywords: Spontaneous hypertension, Renin-Angiotensin System, genomics,
mitochondria, sympathetic nerve activity, kidney
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1.1 Introduction

Hypertension and the chronic elevation of blood pressure (BP) constitute a
primary and significant factor in the development of cardiovascular disease.
Despite major gains in the long-term treatment of hypertension, cardiovascular
disease remains the number one cause of death and disability in developed
countries.

For well over 50 years, scientists have uncovered several

mechanisms believed to govern the long and short-term control of arterial
pressure, with much debate on one major governing factor (Cowley 1992).
Spontaneous hypertension, commonly referred to as essential or primary
hypertension, is a rise in blood pressure of little known cause. Spontaneous
hypertension is a multifactorial disease which accounts for 95% of all cases of
hypertension in humans.

There is a significant positive and continuous

relationship between elevated BP and cardiovascular disease (stroke, heart
failure, myocardial infarction), often resulting in renal disease and even death
(Carretero and Oparil 2000).

Data from the National Health and Nutrition

Examination Survey NHANES have indicated that 50 million or more Americans
have high BP warranting some form of treatment (Burt, Whelton et al. 1995).
Worldwide prevalence estimates for hypertension may be as much as 1 billion
individuals, and approximately 7.1 million deaths per year may be attributable to
hypertension (Burt, Whelton et al. 1995).
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Understanding the mechanisms for the long-term control of BP has important
clinical significance. Because movement-to-movement and long-term stability of
arterial pressure is necessary for survival, mammals have evolved many
redundant controllers that participate in both of these functions. It is thought that
the feedback control systems that provide rapid stabilization of arterial pressure
are fundamentally different than those that determine the long-term level of
arterial pressure. Blood pressure, simply defined, is the pressure exerted upon
the walls of blood vessels. Figure 1.1 represents the mathematic representation
(Ohm’s law) of blood pressure (BP=total peripheral resistance (TPR) X cardiac
output (CO). Arterial pressure is the consequence of several factors that can
influence cardiovascular function including both renal intrinsic mechanisms as
well as extrinsic mechanisms, such as the Renin-Angiotensin System (RAS) and
the sympathetic nervous system.
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1.2 The Kidney, Long-term Control of Blood Pressure and Hypertension

It has been hypothesized that the “set point” for the long-term control of BP
resides in the kidney (Guyton and Coleman 1968; Guyton, Coleman et al. 1972;
GUYTON, COLEMAN et al. 1974). In this model, the set-point of the chronic
renal function curve (Figure 1.2) establishes the steady state relationship
between renal perfusion pressure and urinary excretion of sodium and water,
which in turn affects blood volume and CO (Figure 1.1). This renal-body fluidpressure control system exhibits “infinite feedback gain”, i.e., BP will stabilize
only when intake and output of sodium and water become exactly equal, which
occurs at one pressure level for any given renal function curve and salt intake
level (Guyton 1990).

The renal-BP set-point theory predicts that the kidney

controls BP to maintain its own excretory function and that long-term regulation
of blood volume and CO are paramount to the regulation of BP.

The mechanism for pressure natriuresis and diuresis, developed in a theoretical
analysis by Guyton and Coleman, provides the kidney with the long-term ability
to detect and control arterial pressure (Guyton and Coleman 1968; Guyton,
Coleman et al. 1972; GUYTON, COLEMAN et al. 1974). These seminal works
demonstrated that the mechanism of pressure natriuresis and diuresis is capable
of determining the long-term level of arterial pressure. Because the gain for the
pressure-natriuresis relationship overrides all other regulatory systems in blood
pressure control, the ultimate determinant of BP must be renal handling of
sodium (Adamczak, Zeier et al. 2002).
4

The kidney exerts its powerful diuresis- natriuresis mechanism by both sensing
total extracellular fluid volume (ECFV) and responding to renal perfusion
pressure (Cowley 1992) (Figure 1.3). The quantity of NaCl in the extracellular
fluid compartment and the body’s efficient osmoregulatory system determine total
ECFV. The regulation of ECF osmolality by both the kidney and the brain, and
the rate of fluid entering and exiting the body are important determinants in blood
pressure regulation. Osmoreceptors in the brain detect subtle changes in ECF
sodium concentration and modify thirst and arginine vasopressin (AVP) release
for restoration, conservation or contraction of body water (Andersson, Dallman et
al. 1969; Vereerstraeten and Toussaint 1969). The mechanisms controlling
sodium excretion also contribute importantly to the process of osmoregulation.
The delivery of filtered sodium to the specialized cells of the renal macula densa
(MD) is a major effector sensor for sodium loss in the body. MD cells in the
cortical thick ascending limb (cTAL) are the sensory element of the
juxtaglomerular apparatus (JGA) and play an important role in the control of renal
blood flow, glomerular filtration rate (GFR) and renin release by tubuloglomerular
feedback (TGF), among other things (Sipos, Vargas et al. 2010). It has been
postulated that the MD cells sense Na+, Cl-, or a combination of both, however;
Sipos et al.

(2010) demonstrated that the macula densa cells of the thick

ascending limb are equipped with tubular-flow sensing mechanisms that
contribute to MD cell function, renin release and TGF.

With increased plasma

sodium filtered at the glomerulus, and more sodium (or chloride or flow) to the

5

MD, renin secretion from JGA is reduced. Circulating levels of Angiotensin II
(Ang II) and aldosterone are therefore reduced. Because Ang II and aldosterone
are intimately involved in increased sodium reabsorption, and therefore
determine the rate of sodium loss, it is evident that these and other neural and
endocrine pathways influence osmoregulation via changes in sodium excretion.

This influential model developed by Guyton postulates that the relationship
between renal sodium excretion and BP defines the BP homeostatic set-point.
According to this model, any increase in sodium retention produces an initial
blood volume expansion causing BP to increase via a rise in cardiac output, as
illustrated in Figure 1.3. Eventually, tissue over-perfusion leads to an increase in
peripheral resistance (whole-body autoregulation) that returns resting cardiac
output towards normal. According to this widely held theory, a resetting of the
pressure–natriuresis relationship inevitably leads to hypertension regardless of
the cause of the resetting, whether it be humoral, neural, degenerative or genetic
(Guyton and Coleman 1968).

Renal perfusion pressure (RPP), a direct indicator of arterial pressure, can exert
a powerful influence on the rate of urine excretion as evidenced by the
mechanisms mentioned above (Roman and Cowley 1985; Roman, Cowley et al.
1988). This response can be, and is, blunted by extrinsic factors such as neural
and circulation hormones. However, experiments by Roman et al. showed when
maintaining neural and circulating hormones at constant levels, small elevations
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in RPP by abdominal aortic clamping resulted in large increases of urine output
(Roman and Cowley 1985) . The reflex neural and endocrine systems that effect
the pressure-natriuresis relationship, and hence regulation of body volumes must
be taken into account with understanding long-term BP control. For instance, the
diuretic and natriuretic responses observed from carotid-occlusion or epinephrine
infusion-mediated rises in BP are severely blunted compared to those observed
using aortic clamps (Kirchheim, Ehmke et al. 1987; Sipos, Vargas et al. 2010).
These extrinsic mechanisms include, but are not limited to Ang II,
catecholamines (and renal sympathetic nerve activity), prostaglandins, renal
kinins, atrial natriuetic factor, vasopressin and endothelin (Cowley 1992).

1.2.1 Sympathetic Nervous System and Blood Pressure Control

There has been much controversy over the pressure-natriuresis theory of the
main controller of BP, as it states that it is not determined by the generalized
level of vascular resistance of the systemic circulation (TPR). Total peripheral
resistance is defined simply as the sum of the resistance of all peripheral
vasculature in systemic circulation. As shown in Figure 1.1, a major contributor
to TRP is arteriolar smooth muscle contraction via the autonomic nervous
system. The neural control of circulation operates via parasympathetic neurons
that innervate the heart and three main classes of sympathetic efferents;
barosensitive, thermosensitive and glucosensitive that innervate blood vessels,
the heart, kidneys and adrenal medulla (Guyenet 2006). The barosensitive
sympathetic efferents are under the control of arterial baroreceptors. This large
7

group of efferents has a dominant role in both short-term and potentially longterm BP regulation (Osborn 2005; Guyenet 2006). Their level of activity at rest is
postulated to be an important parameter for long-term BP control. This
background activity is set by a core network of neurons that reside in the rostral
ventrolateral medulla (RVLM), the spinal cord, the hypothalamus and the nucleus
of the solitary tract (NTS). Both variables of BP, TPR and CO are controlled by
some extent by the autonomic nervous system.

CO is dependent on three

regulated variables: ventricular end-diastolic volume; myocardial contractility; and
heart rate. End-diastolic volume is the volume reached by the ventricular
chamber before contraction and is determined by venous pressure, which is
related to blood volume and venous smooth muscle tone, both of which are
under sympathetic control (Osborn 2005). Myocardial contractility and heart rate
are regulated by both the sympathetic and parasympathetic divisions of the
autonomic nervous system. The autonomic nervous system is able to incur rapid
changes via CO and regional arteriolar resistance, which can be associated with
substantial increases in BP. Significant evidence has implicated the autonomic
nervous system and the brain in producing long-term changes in BP (Osborn,
Holdaas et al. 1983; Osborn, Plato et al. 1997; Madden and Sved 2003; Osborn
2005; Littlejohn, Siel et al. 2013). Additionally, peripheral efferents have shown
the same effect.

For instance, increased renal sympathetic nerve activity

(RSNA) results in increased renin secretion rate, increased renal tubular sodium
reabsorption and retention, and decreased GFR and renal blood flow (RBF) with
increased renal vascular resistance (DiBona and Kopp 1997; Osborn, Plato et al.
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1997; DiBona 2000). Thus, increased RSNA represents an important candidate
as a mediator of the normal and abnormal renal function and therefore, the
development of hypertension. Many reports have implicated neurally-mediated
mechanisms in the development of hypertension in several animal models (Judy,
Watanabe et al. 1976; Osborn, Holdaas et al. 1983; Ichihara, Inscho et al. 1997).
Furthermore, removal of renal nerves completely prevented or delayed the onset
of hypertension in numerous animal models of hypertension including humans
with drug-treatment-resistant, primary hypertension (DiBona and Esler 2010).
Elevated SNA is present in most forms of human hypertension (Wyss 1993) and
a causal relationship is suggested by the well-documented antihypertensive
efficacy of sympatholytic drugs (for example, alpha1- or beta-adrenergic receptor
antagonists) (James, Oparil et al. 2014).

The sympathetic efferents that

innervate the kidneys are commonly presented as the only ones that are capable
of influencing the 24-h average BP (Cowley 1992). If this theory is correct, a
more complete knowledge of the neural pathways that selectively regulate renal
SNA could be key to understanding the contribution of the CNS to hypertension.
However, elevated RSNA is probably not the sole mechanism involved in
neurogenic hypertension, and the method by which an increase in SNA raises
the 24-h mean BP has not been established. The most commonly invoked
mechanism is resetting of the renal BP–natriuresis relationship to higher levels of
BP by either a rise in sympathetic tone to the kidney or by hormones whose
production is partly controlled by the autonomic nervous system (for example,
Ang II) (Guyenet 2006).
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1.1.2 The Kidney and its Role in Hypertension

The theoretical basis for the role of the kidney in hypertension is well established
and alterations in kidney function have been identified in the established stage of
every

form

of

hypertension

yet

studied

(Cowley

and

Roman

1983).

Hypertension, therefore, can develop only when something impairs the ability of
the kidney to excrete sodium and water and shifts the relationship between
sodium excretion and arterial pressure towards higher pressures. Renal humoral
mechanisms and transcriptomics related to the development and maintenance of
hypertension will be presented in this doctoral thesis, highlighting the importance
of the kidney in blood pressure control and pathogenesis of the disease.
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Figure 1.1: Comprehensive contributions to control of BP.
Mathematically, BP control is equivalent to Ohm’s law, where BP
is the product of flow (CO) and resistance (TPR). Additionally,
CO is the product of HR and SV. Several factors can directly
influence these cardiovascular parameters, ultimately influencing
to BP. BP=blood pressure, CO=cardiac output, TPR=total
peripheral resistance, SV=stroke volume, HR=heart rate
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Figure 1.2: The Renal Function Cure. Systolic arterial pressure is a
direct function of urine output (UNaV), and hence kidney function. This
relationship exhibits “infinite gain”, i.e., BP will stabilize when intake and
output of sodium are equal, which occurs at one pressure level for any
given renal function curve and salt intake. It is hypothesized that the
manifestation of hypertension occurs only when a rightward shift in the
renal function curve occurs, requiring a higher pressure to excrete the
same level of salt. A rise BP is “essential” to maintain sodium balance.
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Figure 1.3: Basic renal-body fluid feedback mechanism for the long-term
regulation of blood pressure and body fluid volumes. The kidney, it is
hypothesized, contains the long-term homeostatic set-point.
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1.3 Systemic Renin Angiotensin System (RAS): Overview of Components,
Features and Actions

The RAS is an essential regulator of blood pressure, fluid balance, and
cardiovascular function. The RAS produces a family of bioactive angiotensin
(Ang) peptides with a variety of biological and neurobiological activities, with the
most notable peptide being Ang II. The components of the RAS are present in
peripheral tissues such as the vasculature, kidney, brain and heart, all of which
locally produce Ang II (Peach 1977).

The canonical systemic cascade begins

with the release of the aspartyl protease renin from the JG cells of the kidneys
leading to the conversion of circulating angiotensinogen from the liver to inactive
angiotensin-I (Ang I) which, in turn, is converted to three different peptides; Ang II
by the dipeptyl carboxypeptidase angiotensin-converting enzyme (ACE) located
ubiquitously along vascular walls and secreted into the lungs and kidneys, Ang(1-7) by neprilysin and Ang-(1-9) by the zinc metalloprotease ACE2 (Figure 1.4).
Ang-(1-9) is metabolized by the metalloendopeptidase neprilysin to form Ang-(17), which is hydrolyzed by ACE to form Ang-(1-5). Ang II is degraded into the
smaller, active peptides Ang III, Ang IV and Ang (1-7) by aminopeptidase A,
aminopeptidase N and ACE2, respectively. Ang II is also converted to Ang-(1-4)
by neprilysin (Lavoie and Sigmund 2003).

Ang II primarily binds two G-protein coupled receptors, Ang II type 1 (AT ) and
1

Ang II type 2 (AT ) receptor, to produce both harmful and physiological effects on
2

cardiovascular health (de Gasparo, Catt et al. 2000; Lavoie and Sigmund 2003).
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Most of the classical actions of Ang II such as vasoconstriction, sodium retention,
aldosterone release and sympathetic activation are facilitated by the AT
receptor. There are two AT receptor isoforms in rodents, AT
1

only one in humans (de Gasparo, Catt et al. 2000).

1A

1

and AT , and
1B

Activation of the AT2

receptor generally has effects that are contrary to AT1 receptor actions-mainly
vasodilation, natriuresis and antiproliferation (Bottari, de Gasparo et al. 1993). In
humans, the AT1 receptor is located in blood vessels, heart, kidney, adrenal
glands and liver while the AT2 receptor is mainly expressed in fetal tissue, with
relatively low amounts present in adult tissue (Matsubara 1998). Ang-(1-7),
acting through the G-protein Mas receptor, has actions that are contrary to the
effects of Ang II, such as vasodilation, natriuresis and antiproliferation(Santos,
Simoes e Silva et al. 2003). Ang III (Ang 2-8) is thought to exert its actions at the
AT1 receptor and may be responsible for effects associated with Ang II,
especially in the brain (Wright, Bechtholt et al. 1996). Ang IV binds the AT1 and
AT receptors with low affinity and binds its own AT4 receptor.
2

The RAS has generally been classically affiliated with blood pressure control and
salt and water balance. Nevertheless, the RAS is continually emerging as a
complex system involved in many physiological and pathophysiological
conditions outside of the classic hemodynamic and osmoregulatory effects. The
RAS contributes to oxidative damage (Sachse and Wolf 2007), insulin resistance
(Henriksen 2007) and cell-growth (Pawlikowski, Melen-Mucha et al. 1999) and
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has been implicated in the pathogenesis of the metabolic syndrome, diabetes,
renal damage and hypertension.

1.3.1Cardiovascular Regulation

The body has several mechanisms to control blood pressure. These
mechanisms, such as the actions of the RAS, can alter cardiac output, the blood
volume in the bloodstream and vasoactivity of the arteries. The RAS has
profound influence on cardiovascular and renal function due to its various actions
throughout the body. Ang II is a potent vasoconstrictor, constricting arteries and
veins to increase blood pressure. Ang II is also involved in fluid reabsorption.

Blood pressure regulation is a separate but not mutually exclusive process: both
quick BP adjustments via baroreflexes and through long-term control involving
the kidneys. The baroreflexes are mediated by the sympathetic and
parasympathetic nervous systems.

The baroreflex, which is a negative-

feedback system, augments blood pressure in a matter of seconds to minutes.
When blood pressure rises, the carotid and aortic sinuses distend resulting in
activation of the baroreflex which adjusts sympathetic and parasympathetic
activity accordingly. Afferent baroreceptor input suppresses sympathetic activity
through a multisynaptic pathway which starts with excitatory fibers synapsing at
the NTS. The NTS then sends excitatory (glutamatergic) projections to the
caudal ventrolateral medulla (CVLM) and nucleus ambiguous (NA).

The

activated CVLM sends inhibitory (GABAergic) fibers to the RVLM, which then
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decreases sympathetic nerve activity to the heart and vasculature. Activation of
the NA will decrease heart rate by increasing parasympathetic nerve activity to
the heart via the vagus nerve. The blood pressure is reset back to its original
point. The RAS interacts with both these systems to help maintain and regulate
cardiovascular function. Ang II modulates baroreflex function by decreasing the
sensitivity of the gain of the baroreflex (Brooks 1995).

Ang II acts at AT

1

receptors in the NTS to decrease the baroreflex sensitivity (Diz, Jessup et al.
2002), whereas Ang-(1-7) enhances the baroreflex sensitivity also by acting at
the NTS (Ferrario, Chappell et al. 1997).

The kidney is involved in more long-term regulation of blood pressure and the
RAS has both direct and indirect effects on the kidney. The RAS partners with
the kidney to control blood pressure by maintaining salt and water balance. Ang
II does this through its direct and indirect effects on water and salt reabsorption,
which leads to an increase in blood pressure. Under physiological conditions, the
RAS ensures that blood pressure does not drop too low and to maintain proper
perfusion and blood flow to tissues and organs that need it the most under these
circumstances. However, chronic activation of Ang II may lead to hypertension
and damage the various organs and tissues of the body (Lavoie and Sigmund
2003).

Ang II has a direct effect on the proximal tubules to increase salt

reabsorption. Indirectly, Ang II causes the adrenal cortex to secrete the
mineralcorticoid aldosterone which acts on the distal tubules and collecting ducts
to cause conservation of sodium, water retention and potassium secretion. The
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effects that Ang II has on renal blood flow and GFR vary depending on the
situation.

Ang II constricts the afferent and efferent arterioles and incites

contraction of the mesangium, resulting in a decrease in renal blood flow,
glomerular filtration rate and filtered sodium load (Brewster and Perazella 2004).
Ang II decreases the surface area for glomerular filtration by constricting the
mesangial cells. The effect on the efferent arteriole is greater in part due to its
smaller basal diameter. Efferent arteriole constriction decreases renal blood flow
and increases glomerular filtration by increasing glomerular capillary pressure.
This increase in filtration fraction causes an increase in the peritubular vessel
oncotic pressure and a decrease in the hydrostatic pressure, which also occurs
in the renal interstitium. This pressure gradient allows sodium and water to move
from the proximal tubule to the interstitium. Ang II decreases medullary blood
flow and reduces renal interstitial pressure which decreases water and sodium
excretion (Brewster and Perazella 2004). Ang II inhibits pressure-natriuresis and
it is thought to be a TGF modulator because it augments TGF sensitivity (Vallon
2003). Furthermore, Ang II is involved in the proliferation of nephron cells
(Zhang, Guo et al. 2004).

Ang II exerts influence on distinct ion channels along the nephron as well. Ang II
+

+

enhances the sodium/hydrogen (Na /H ) ion anti-porter activity on the luminal
membrane of proximal tubules (Brewster and Perazella 2004) and in the early
and late distal segments (Wang and Giebisch 1996). The action of Ang II to
augment distal tubule sodium reabsorption complements the effect in proximal

18

tubules to create a greater efficiency of sodium retention. It stimulates the
Na+/HCO3- symporter and Na+/K+ pump in the proximal tubule basolateral
membranes (Brewster and Perazella 2004). Ang II acts at the Na+/K+ pump in
the medullary thick ascending limb and at the epithelial sodium channel (ENaC)
of the cortical collecting tubules.

1.3.2 Neural Effects of RAS

Ang II plays a prominent role in a variety of neural mechanisms. It interacts with
neurotransmitters and is itself considered a peptidergic neurotransmitter under
certain conditions (McKinley, Albiston et al. 2003). It stimulates thirst centers in
the brain, the desire for salt and is involved in vasopressin release. It facilitates
norepinephrine release from sympathetic nerve endings and is known to
decrease baroreflex function (DiBona 2001). Some of the central mechanisms
are described in more detail below.

1.3.3 Thirst Sensation

The thirst mechanism is one way to increase fluid volume, leading to volume
expansion and a subsequent increase in blood pressure. Stimulation of AT

1

receptors in the brain causes an increase in water intake, salt appetite and blood
pressure. Intracerebroventricular (ICV) administration of Ang II increases the
dipsogenic response and blood pressure and the subfornical organ (SFO), which
lies outside the blood-brain barrier, is reported to be involved in this dipsogenic
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mechanism (McKinley, Albiston et al. 2003). Dehydration causes a significant
increase in Ang II binding sites in the SFO which could make circulating Ang II
more efficient as a thirst stimulus (Saavedra 2005). Ablation studies showed that
the thirst effect is facilitated by Ang II binding to receptors in the SFO and
organum vasculosum of the lamina terminalis (OVLT) and Ang II injected into
these forebrain areas leads to an increased blood pressure (Andersson, Eriksson
et al. 1995) . The median preoptic nucleus (MnPO) has also been shown to be
involved in thirst because Ang II micro-injected directly into the MnPO promotes
drinking in rats (McKinley, Albiston et al. 2003). The MnPO is suggested to be an
angiotensinergic synapse site that mediates thirst caused by Ang II as the SFO
sends efferent projections to the MnPO. Projections are also sent to the
paraventricular nucleus of the hypothalamus (PVN), which facilitates vasopressin
production and secretion (McKinley, Albiston et al. 2003).

1.3.4 Ang II and Vasopressin Release

AVP, or anti-diuretic hormone (ADH), is a hormone secreted by the posterior
pituitary gland that regulates water reabsorption in the collecting duct in kidneys
as well as act as a potent vasoconstrictor. It increases water permeability of the
distal convoluted and collecting tubules by inserting aquaporin channels into the
apical membranes of the tubules/collecting duct epithelial cells. Circulating Ang
II stimulates vasopressin release mainly by binding receptors in the SFO and
possibly in the OVLT (Andersson, Eriksson et al. 1995).

The vasopressin

response to systemic Ang II is inhibited in rats following SFO ablation (Simpson,
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Epstein et al. 1978). ICV injection of Ang II activates circumventricular organ
(CVO) neurons, which directly or indirectly project to vasopressin-producing
neurons in the paraventricular and supraoptic nuclei of the hypothalamus (SON)
(McKinley, Albiston et al. 2003). Coadministration of Ang II and AT receptor
1

antagonist losartan decreases vasopressin secretion, further documenting Ang
II’s role in AVP release (76).

1.3.5 Ang II and the Sympathetic Nervous System

The RAS and SNA are two major extrinsic regulatory mechanisms for blood
pressure and fluid homeostasis. Ang II activates the SNA at various levels and is
known to be a tonic stimulus of RSNA (DiBona 2001).

Both central and

circulating Ang II may influence SNA. Ang II injected into the RVLM increases
SNA and arterial pressure (Andersson, Eriksson et al. 1995). Microinjection of
angiotensin II receptor blockers losartan and candesartan into the RVLM
decreased the basal level of RSNA and heart rate, with candesartan also
decreasing BP (DiBona and Jones 2001). Bilateral injection of Ang II receptor
antagonists into the RVLM decreased BP similar to the decrease revealed
subsequent to blockade of spinal sympathetic outflow (DiBona, Jones et al.
1996). ICV injection of losartan attenuated basal RSNA in proportion to the level
of RAS activation (DiBona, Jones et al. 1996).

Activation of the PVN by

bicuculline leads to an increase in arterial pressure, heart rate and RSNA, which
is primarily mediated by excitatory angiotensinergic projections from the PVN to
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the RVLM. Furthermore, losartan injected into the ipsilateral RVLM decreases
the renal sympathoexcitatory, pressor and tachycardic responses to bicuculline
injected into the PVN (DiBona, Jones et al. 1996).

As a counter to Ang II’s effects, Gironacci et al. (2004) showed that Ang-(1-7)
decreased norepinephrine release from the hypothalamus through the Mas
receptor, suggesting that Ang-(1–7) may decrease SNSA leading to an
antihypertensive effect.

Ang II influences renal function through central mechanisms, mainly involving
activation of the renal sympathetic nerves.

RSNA and its arterial baroreflex

control are mediated by changes in RAS activation. Circulating Ang II can act at
areas such as the SFO and area postrema (AP) to modulate SNA (DiBona
2001). Circulating Ang II acting at the AP may increase peripheral SNA through a
direct excitatory projection from the AP to RVLM (DiBona 2001). ICV injection of
losartan in conscious rats did not affect basal levels of BP, but decreased basal
RSNA suggesting that Ang II tonically influences basal levels of RSNA and its
arterial baroreflex (DiBona, Jones et al. 1996). Brain Ang II activates AT

1

receptors to suppress the baroreflex control of RSNA and increases sodium
reabsorption by stimulating renal nerve activity and catecholamine release within
the kidney (van den Meiracker and Boomsma 2003).
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The renal sympathetic nerves innervate all the major structural elements of the
kidney including the afferent and efferent arterioles, JG cells, mesangium,
vascular smooth muscle cells (VSMC) and tubules (proximal, distal and
ascending limb of loop of Henle, collecting duct), with some areas being more
innervated than others.

There is also differential innervation of the three

intrarenal effectors (JG cells, tubules, vasculature) such that some renal
sympathetic nerve fibers only make contact with one of the three and some fibers
make contact with multiple effectors (DiBona and Kopp 1997). Low frequency
renal nerve stimulation stimulates renin release from the JG cells via a β-1
adrenoceptor effect, increases reabsorption of sodium and water in the tubules of
the nephron, and causes renal vasoconstriction (Osborn, Holdaas et al. 1983).
Activation of the renal nerves generally leads to a decrease in renal blood flow
and GFR due to the constriction of the vasculature. Renal nerve activation is one
of the more important mechanisms leading to sodium retention since it increases
sodium and water retention throughout the entire nephron and can also induce
sodium retention by increasing renin production and by mediating the resistance
of the afferent arterioles. Increased renal nerve activity is thought to play a role
in many pathologic conditions such as hypertension (Winternitz, Katholi et al.
1980; Hendel and Collister 2006), myocardial infarction (Souza, Mill et al. 2004)
and renal failure. Renal denervation prevented hypertension in male SD rats
with chronic renal failure (Campese, Kogosov et al. 1995) and in genetically
hypertensive rats delays the development of hypertension (Liard 1977;
Winternitz, Katholi et al. 1980; Diz, Nasjletti et al. 1982; Kline 1987). Recently,
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renal denervation in humans has shown to be extremely effecting in attenuating
elevated arterial pressure in treatment-resistance patients (DiBona and Esler
2010).

These studies highlight the importance of renal nerves in the

manifestation and maintenance of hypertension.

1.3.6 Local (Tissue) RAS

The idea of local or tissue RAS was first conceptualized upon the confirmation
that there was a separate brain RAS (local Ang II production), independent of the
circulating RAS. It is now well established that many tissues and organs contain
their own local RAS, including the kidney, heart, vessels, adrenal gland,
pancreas and brain (Lavoie and Sigmund 2003; Bader and Ganten 2008). The
local systems seem to be regulated independently of the circulating RAS though
interactions exist. The actions of the tissue RAS’s may occur in the cell that
generates the peptides (intracrine and autocrine), in neighboring cells (paracrine)
or through the bloodstream to a specific organ or tissue (endocrine). In the brain,
the AT receptor is located in the SFO, OVLT, NTS, APS, PVN, CVLM, RVLM,
1

dorsal medulla, the lateral parabrachial nucleus and the MnPO (Diz, Jessup et al.
2002; McKinley, Albiston et al. 2003; Veerasingham and Raizada 2003). These
regions are involved in regulating cardiovascular function and/or body fluid and
electrolyte balance. Though all components of the RAS are located in the brain,
not a single cell contains all of the constituents of the RAS (Saavedra 2005; von
Bohlen und Halbach and Albrecht 2006).
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Regulation and specific mechanisms of the brain RAS in normal physiology and
pathophysiology are not completely understood. Studies show that the brain RAS
activates sympathetic outflow, inhibits the baroreflex, stimulates thirst, and
contributes to neurogenic hypertension (Steckelings, Lebrun et al. 1992; Lavoie
and Sigmund 2003; van den Meiracker and Boomsma 2003). In rats with chronic
renal failure, the brain RAS is upregulated, resulting in sympathetic overactivity
and hypertension (Nishimura, Takahashi et al. 2007).

Transgenic mice with

increased brain Ang II production developed hypertension and an increase in salt
appetite and drinking volume (Morimoto, Cassell et al. 2001).

1.3.7 Brain RAS

It is reported that there are two RASs in the brain; an endogenous system
located within the neurons inside the blood brain barrier and a system in the
CVOs and cerebrovascular endothelial cells that respond to circulating Ang II of
peripheral origin (Saavedra 2005). The two systems are interconnected and the
brain responds to both.

Angiotensinogen is produced mainly in astrocytes

(McKinley, Albiston et al. 2003). Renin mRNA is present in the central nervous
system (CNS), but concentrations are low (McKinley, Albiston et al. 2003). High
concentrations of ACE are located in the AP, SFO, OVLT and median eminence.
Aminopeptidase A and N are both located in the rodent brain. Ang I, Ang II, Ang
III and Ang-(1-7) have been discovered in brain tissue, however Ang III and Ang(1-7) are found in very low concentrations (McKinley, Albiston et al. 2003).
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1.3.8 Kidney RAS

All

of

the

RAS

components

are

present

within

the

kidney

with

compartmentalization in the tubules and interstitium as well as intracellular
accumulation (Kobori, Nangaku et al. 2007). In fact, it is reported that there are
two distinct intrarenal RASs; vascular (renal vessels, arterioles and glomeruli)
and tubulointerstitial (proximal tubules and associated interstitium). Intrarenal
Ang II, which can be formed independent of the circulation, may also be a result
of circulating Ang II that is internalized into proximal tubule cells by the AT

1

receptor. In addition, Ang II may be formed from systemically delivered Ang I
(Navar, Harrison-Bernard et al. 1999). Angiotensinogen is located mostly in the
proximal tubule cells and can be secreted directly into the tubule lumen (Navar,
Prieto et al. 2011). In general, renin from the JG cells is the primary source of
both circulating and intrarenal renin. However, renin is also found in other areas
of the kidney and is produced by the proximal tubule cells, as well as the distal
nephron segments. Ang I and Ang II formation in the tubule lumen may occur
subsequent to angiotensinogen secretion because some renin is filtered and/or
secreted from juxtaglomerular or proximal tubule cells. ACE is located on the
proximal tubule brush border and converts Ang I to Ang II (Kobori, Nangaku et al.
2007). ACE2 is present in renal endothelial and tubule cells and in glomerular
podocyte and mesangial cells (Donoghue, Hsieh et al. 2000; Reich, Oudit et al.
2008). Previous work demonstrates that Ang I and Ang II are located with renin
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in the juxtaglomerular apparatus cells and vascular smooth muscle cells of the
afferent arteriole (Navar, Prieto et al. 2011). However, Ang I and Ang II are
mainly located in the tubular and interstitial fluid compartments (Navar, Prieto et
al. 2011). The AT receptor is extensively dispersed throughout the kidney. It is
1

located in the vascular smooth muscle cells of the afferent and efferent arterioles,
glomeruli (mesangial cells and podocytes) and proximal tubule cells (brush
border and basolateral membranes). Receptor subtypes are also found in the
juxtaglomerular and macula densa cells, thick ascending limb, distal tubules,
vasa recta, arcuate arteries and cortical collecting ducts (Carey and Siragy 2003;
Kobori, Nangaku et al. 2007). The distribution of the two AT receptor subtypes
1

in rodents is different with the AT
The AT
AT

1A

1A

1A

subtype being the more prevalent of the two.

is present in all nephron segments and AT

1B

is more abundant than

in the glomerulus (66). The AT receptor is present in the afferent arteriole,
2

mesangium, proximal tubule, collecting ducts, parts of the renal vasculature,
interstitial cells and in glomerular endothelial and epithelial cells (Bader and
Ganten 2008).

The intrarenal RAS is regulated differently than the circulating RAS as shown by
the fact that proximal tubule angiotensinogen, collecting duct renin and tubular
AT receptors are increased by intrarenal Ang II (Kobori, Nangaku et al. 2007).
1

Intrarenal RAS activation may contribute to hypertension, renal injury, diabetes
and metabolic syndrome.

Ang II produced in the kidney directly induces
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podocyte injury and apoptosis through AT receptor activation independent of
1

hemodynamic changes (Kobori, Nangaku et al. 2007).

Ang II induces

proliferation of glomerular endothelial cells, mesangial cells and fibroblasts
(Rüster and Wolf 2006). Additionally, hyperglycemia, proteinuria and renal injury
activate the intrarenal RAS (Rüster and Wolf 2006).

Inhibition of the RAS has proven to be renoprotective against diseases other than
hypertension. The American Diabetes Association suggest that ACE inhibitors
and angiotensin II receptor blockers (ARBs) be considered as first-line therapy to
slow renal disease progression in hypertensive and type 2 diabetic patients
(Vejakama, Thakkinstian et al. 2012). In hypertensive, type 2 diabetic patients,
irbesartan delayed the increase in serum creatinine 24% more slowly than the
placebo group and 21% slower than the group that received the calcium channel
blocker amlodipine (Rossing, Schjoedt et al. 2005). This renoprotective effect
was independent of the blood pressure lowering effect (Lewis, Hunsicker et al.
2001) as ARBs have been shown to benefit normotensive diabetic patients as
well (Coyle, Gardner et al. 2004). ACE inhibitors decrease mesangial expansion,
glomerulosclerosis, loss of glomeruli, tubular atrophy, interstitial fibrosis and
proteinuria (Gansevoort, Sluiter et al. 1995; Ferder, Inserra et al. 2003).
Proteinuria is also decreased in the presence of AT receptor blockers (Mizuno,
1

Sada et al. 2006).

Losartan and enalapril reduced glomerular and

tubulointerstitial fibrosis, tubular atrophy and increased the number mitochondria
and improved mitochondrial function (Ferder, Inserra et al. 2003).
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The RAS has been suggested to play a pathogenic role in the development of
hypertension in Okamoto-Aoki Spontaneously Hypertensive Rat (SHR). These
RAS implications are directly related in part to activation of sympathetic nerve
activity. Numerous studies have demonstrated that administration of either
angiotensin-converting ACE inhibitors or angiotensin receptor antagonists to
immature SHRs prevents development of hypertension (Madeddu, Anania et al.
1995) . In the SHR, brain levels of Ang II and renin are elevated after the onset
of adult hypertension (Phillips and Kimura 1988), hypothalamic angiotensinogen
mRNA is more abundant (Yongue, Angulo et al. 1991), and SHRs exhibit
elevated AT1r mRNA in the brain and kidney compared to normotensive Wistar
Kyoto (WKY) rats (Raizada, Sumners et al. 1993; Cheng, Wang et al. 1998).
Subsequently, losartan, a potent AT1r antagonist, normalizes blood pressure in
SHRs when delivered intravenously (IV) or ICV (Medina, Cardona-Sanclemente
et al. 1997).

In addition to pharmacological blockade, Gyurko et al. (1993)

demonstrated that inhibiting the brain RAS by antisense inhibition of
angiotensinogen and AT1 receptor genes lowers blood pressure in adult SHRs,
potentially

linking

genetic

contributions

of

the

RAS

to

hypertension.

Abnormalities in AT1r function have been linked to several pathological
conditions such as hypertension, cardiac and renal hypertrophy, and proliferation
of vascular smooth muscle cells. Each of these pathologies alone or together
may critically contribute to the onset and maintenance of hypertension. Taken
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together, SHRs exhibit an exacerbated RAS, which in turn, plays a role in
development of elevated arterial pressure and propagation of hypertension.

30

Figure 1.4: Overview of the renin-angiotensin system (RAS).
AGT indicates angiotensinogen; Ang, angiotensin; ACE,
angiotensin-converting enzyme; ACE2, angiotensin-converting
enzyme 2; AT1R, angiotensin type 1 receptor; AT2R,
angiotensin type 2 receptor; MasR, Mas (Conti, Cassis et al.
2012)
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1.4 Nuclear Genetics and Genomics of Spontaneous Hypertension

Significant effort has been devoted to defining the pathogenesis of blood
pressure variation. The difficulty in defining the causes of hypertension from
physiological studies alone motivated the application of genetic approaches to
hypertension. Identification of genes underlying blood pressure variation has the
capacity to define primary physiologic mechanisms underlying this trait, thereby
clarifying disease pathogenesis, identifying pathways and targets for improved
therapeutic intervention, providing opportunity for preclinical diagnosis, and
allowing treatment tailored to individual patients. There is substantial evidence for
genetic

influence

on

blood

pressure.

Twin

studies

document

greater

concordance of blood pressures of monozygotic than dizygotic twins (Feinleib,
Garrison et al. 1977) and population studies demonstrate greater similarity of
blood pressure within families than between families (Longini, Higgins et al.
1984). This familial aggregation of blood pressure is not simply attributable to
shared environmental effects since adoption studies show greater concordance
of blood pressure among biological siblings than adoptive siblings living in the
same household (Biron, Mongeau et al. 1976) (Rice, Vogler et al. 1989). Single
genes can impart large effects on blood pressure as demonstrated by rare
Mendelian forms of high and low blood pressure (Lifton 1996). Although these
Mendelian traits have quantitatively large effects in affected individuals, they are
quite rare and likely account for a very small fraction of the variation in blood
pressure in the human population (Lifton, Gharavi et al. 2001).

32

The polygenic nature of essential hypertension and its dependence on
environmental factors complicate the identification of causative genetic factors
(Garrett, Dene et al. 1998). Significant progress has been made to map the
genes involved in blood pressure regulation. Genome scans have been carried
out in rats, mice and humans and have revealed several potential chromosome
regions that may contain genes involved in the pathogenesis of spontaneous
hypertension. Molecular genetic analysis proves that BP regulation is polygenic
and there is good evidence for several BP related quantitative trail loci (QTL) on
nearly every rat chromosome (Deng, Dene et al. 1994; Schork, Krieger et al.
1995; Hopkins and Hunt 2003; Laulederkind, Hayman et al. 2013).

Linkage

studies in populations derived from the SHR indicate potential BP QTL.
Recently, Atanur et al. (2010) sequenced the SHR/Olalpcv genome, identifying
3.6 million high quality SNPs between the SHR/Olalpcv and BN reference
genome. Genomic regions containing genes that have been previously mapped
as cis-regulated expression (QTL) contained several SNPs, short indels, and
larger deletions which suggests potential functional effects on gene expression.
Atanur et al. found 688 genes that overlap with regions showing copy number
variation (CNV) that represent genes for immunological, neurological or
mechanical function. The high statistical significance of these functional variants,
coupled with the known metabolic, cardiovascular and neurobehaviorial
phenotypes described in the SHR (Okamoto and Aoki 1963), suggests alteration
of these gene classes may directly relate to the phenotypes manifested by SHRderived strains (Rapp 2000).

This sequence information supports previous
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studies of experimental crosses and congenic strains that led to the identification
of CNV in rat Cd36 gene as a cause of CD36 deficiency, insulin resistance,
dyslipidemia, and hypertension in the SHR strain (Aitman, Glazier et al. 1999;
Pravenec, Landa et al. 2001; Pravenec, Churchill et al. 2008). This highlights the
potential functional significance of other CNVs detected in the SHR genome.

1.4.1 Renin-Angiotensin System Genes and Hypertension

With the abundance of knowledge on the role of both circulating and tissue RAS
in BP control, it is hypothesized that genetic variability in one or more of the RAS
components could account for the pathogenesis of hypertension.

A large

number of patients with hypertension and cardiovascular disease are on ACE
inhibitors or AT1r antagonists.

Recognizing a potential genetic influence on

protein expression would be vital to the treatment and prevention of essential
hypertension. The mouse renin gene (Ren) was the first gene of the RAS to be
cloned (Burnham, Hawelu-Johnson et al. 1987).

Several investigators have

established transgenic models expressing the mouse Ren-2 gene (mRen-2).
High expression of the transgene has been shown to cause severe hypertension,
associated with increased renin activity and local Ang II formation, while
suppressing plasma RAS (Rothermund and Paul 1998). Restriction mapping and
linkage analysis have been used to study the association of renin and
hypertension, but whether the renin locus is associated with hypertension is still
under debate. Cloning of the human genes coding for angiotensinogen (Agt)
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(Jeunemaitre, Soubrier et al. 1992), angiotensin-converting enzyme (ACE)
(Rigat, Hubert et al. 1990) and the AT1 receptor (Agtr1a/b) (Bonnardeaux, Davies
et al. 1994) has led to the discovery of several polymorphisms that may play a
role as risk factors for hypertension. Higher levels of angiotensinogen have been
demonstrated to be associated with higher levels of Ang II (Walker, Whelton et
al. 1979).

In addition, transgenic mice with overexpression of a rat

angiotensinogen gene develop hypertension, and knockout mice with a disrupted
gene and absent production of angiotensinogen develop low BP (Jeunemaitre,
Soubrier et al. 1992).

In 1990, Rigat et al (1990) produced evidence for an insertion/deletion (I/D)
polymorphism (287bp insert/deletion) in intron 16 of the ACE gene was strongly
associated with circulating ACE concentrations.

In individuals that were

homozygous for the D allele (D/D), plasma ACE concentrations were twice those
of persons homozygous for I allele (I/I). Zhu et al. (Zhu, McKenzie et al. 2000)
later reported that the functional mutation was not the I/D variant, but a variant
downstream that exists in linkage disequilibrium that is responsible for changes
in plasma ACE levels. Nevertheless, there is significant evidence that the ACE
gene controls plasma ACE concentrations and therefore could have a causal
relationship with hypertension.

For the Agtr1a/b gene, a SNP has been described in which either adenine (A) or
a cytosine (C) base (A/C tranversion) in position 1166 in the 3’ untranslated
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region of the gene (Joe and Garrett 2005). The physiological importance of this
polymorphism is uncertain because of its location in the untranslated region,
however several studies have shown that it was associated with hypertension
(Joe and Garrett 2005), left ventricular hypertrophy (Takami, Katsuya et al.
1998), coronary artery disease and myocardial infarction (Bonnardeaux, Davies
et al. 1994), and progression of diabetic nephropathy (Tomino, Makita et al.
1999).

The silent A1166C SNP has been associated with severe forms of

hypertension, and in particular in resistant hypertensive patients taking two or
more antihypertensive drugs (Bonnardeaux, Davies et al. 1994; Kainulainen,
Perola et al. 1999). However, the relationship between this SNP and BP shows
great diversity within human populations (Baudin 2002). The most likely scenario
is that the polymorphic transversion in not functional, but may occur in linkage
disequilibrium with an unidentified functional variant (Bonnardeaux, Davies et al.
1994).

Although significant progress has been made, the exact form of the underlying
genetic mechanisms remains unanswered. Multiple approaches will be needed
to achieve this assignment; however, the sequencing of the SHR nuclear
genome by Atanur et al. (2010) will provide a great source for complete
functional elucidation between hypertensive and normotensive rats of SHR origin
at the molecular level.

This provides substantial insight to the genetic

components of human essential hypertension.
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It is the hope that by identifying

nuclear genes contributing to hypertension, that we can switch from treatment to
prevention of hypertension and cardiovascular disease.
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1.5 Mitochondrial Genomics/Dynamics and Hypertension

Eukaryotic cells contain a number of organelles with specialized functions like the
mitochondria. Mitochondria are broadly known as double-membrane-bounded
organelles, which perform a number of indispensable functions for the life of most
eukaryotic cells. Their main function is the production of energy in the form of
ATP via the citric acid cycle and the oxidative phosphorylation system
(OXPHOS), but they are also involved in the biosynthesis of many metabolites
like pyrimidines, amino acids or cellular iron sulphur cluster proteins (BereiterHahn 1990; Attardi, Yoneda et al. 1995; Lill, Diekert et al. 1999). Mitochondria
also control the ability of the cell to generate and detoxify reactive oxygen
species (ROS) (Nicholls, Vesce et al. 2003).

Beside their role as ATP

generators, mitochondria have also the ability to remove Ca2+ ions out of the
cytosol and accumulate them in their matrix (Deluca and Engstrom 1961). The
release of mitochondrial pro-apoptotic factors like cytochrome c into the
cytoplasm can induce a signaling cascade, which plays a prominent role in
apoptotic cell death (Hengartner 2000).

The citric acid cycle, which takes place in the mitochondrial matrix, is a central
metabolic pathway involved in the catabolic oxidation of substrates (Krebs 1970).
Acetyl-CoA, which is generated by the decomposition of nutrients such as
glucose, transfers two carbon acetyl groups to oxaloacetate to generate citrate.
The citrate is metabolized through a series of chemical transformations and
releases two carboxyl groups as CO2. The energy-rich electrons generated by
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the cycle are transferred to NAD+/NADP+ and FAD+ to form NADH/NADPH and
FADH2. Several substances like NADH, ATP and Ca2+ regulate the citric acid
cycle (Krebs 1970).

The electrons generated via the citric acid cycle are transferred to the
multisubunit enzyme complexes of the respiratory chain.

The OXPHOS is

embedded in the inner mitochondrial membrane. Functionally, it is composed of
the five enzyme complexes: NADH dehydrogenase (Complex
dehydrogenase (Complex

I),

succinate

II), cytochrome bc1 complex (Complex

III),

cytochrome c oxidase (Complex IV, COX) and ATP synthase (Complex V) as
well as the two electron carriers coenzyme Q and cytochrome c (Hatefi 1985).
The electrons are transferred to oxygen to generate water at Complex IV. The
transport of electrons via the respiratory chain generates a proton gradient
across the membrane which is used to synthesize ATP by Complex V (Hatefi
1985).

Molecular genetics research and hypertension has been primarily focused on the
nuclear genes (nDNA), despite the fact that mitochondria are present in multiple
copies in each cell, have their own genome, and mitochondrial dysfunction has
recently been implicated in a wide variety of genetic disorders (Aitman, Glazier et
al. 1999; Taylor and Turnbull 2005).

Mitochondrial DNA is transmitted through

the oocyte’s cytoplasm at fertilization, hence, are nearly strictly maternally
inherited. Alterations in mitochondrial function are observed in conjunction with
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increase in age and the development of hypertension in rodents and humans
(Hofmann, Jaksch et al. 1997; Shin, Tanaka et al. 2000; Schwartz, Duka et al.
2004; Chan, Wu et al. 2009; Kumarasamy, Gopalakrishnan et al. 2010).
Mitochondria are the principal generators of cellular ATP by OXPHOS.
Mammalian mtDNA encodes 37 genes, including 13 polypeptide genes, all of
which encode essential components of OXPHOS. It also encodes the 12S and
16S ribosomal RNA (rRNA) genes and the 22 transfer RNA (tRNA) genes
required for mitochondrial protein synthesis (Figure 1.5).

The rat mtDNA

genome varies between 16,307 and 16,315 bp in size. The size variation is due
to insertions/deletions in the replication origin, D-loop, 16S rRNA, and NADH
dehydrogenase subunit 2 (Schlick, Jensen-Seaman et al. 2006).

Each

mitochondrion contains one to ten copies of its genome and each cell
encompasses hundreds to thousands copies of mitochondria. The faster rate of
mtDNA replication, however, is not without consequences, particularly, in an
environment that is high in reactive oxygen species (ROS). The rare error rates
of DNA replication and editing enzymes increase in the presence of oxidative
modified nucleotides and enzymes. Hence, mtDNA has ~16 times higher
mutation accumulation rate than the nDNA (Richter, Park et al. 1988). Mutations
could initiate a vicious cycle of impaired mitochondrial functions, increased ROS,
higher error rates of DNA polymerases and editing enzymes and further
accumulation of mutated mtDNA. Given the presence of thousands of copies of
mtDNA in each cell, mutations generate an admixture of wild type and mutant
mtDNA, which is referred to as heteroplasmy, as opposed to homoplasmy, when
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all copies of mtDNA are identical. Heteroplasmy in mtDNA in somatic cells, as
the mitochondria replicates, increases with age. Accordingly mitochondrial
mutations and dysfunctions have been implicated in various age-dependent
phenotypes including cellular senescence and metabolic disorders.

Base substitutions in mtDNA protein synthesis genes can result in multisystem
disorders with a wide range of symptoms (Shin, Tanaka et al. 2000; Schwartz,
Duka et al. 2004; Wallace 2005). Recently, Schlick et al. (2006) sequenced the
mtDNA of 10 commonly used inbred rat strains.

Analysis showed 11 single

nucleotide polymorphisms (SNPs) within the tRNA genes, 6 in the 12S rRNA,
and 12 in the 16S rRNA including 3 indels. Also, 14 SNPs and 2 indels were
found in the D-loops.

Pravenec et al. (Pravenec, Churchill et al. 2008)

investigated whether naturally occurring variation in the mitochondrial genome of
SHRs and BN rats could be linked to risk factors for type 2 diabetes. Sequence
analysis revealed distinct differences between the 2 strains, revealing
polymorphisms of functional significance in seven of 13 mRNA genes, five of 22
tRNA genes and both rRNA genes. The mRNA variants were predicted to cause
amino acid substitutions in mitochondrial cytochrome oxidase subunit 1, ATP
synthase

subunit

6,

ATP

synthase

subunit

8,

cytochrome

b,

NADH

dehydrogenase subunit 2, and NADH dehyrogenase 6. Some of these amino
acid substitutions are located within 0-3 residues of mutation sites known to be
associated with human diseases (Pravenec, Churchill et al. 2008). Variations in
the tRNA genes were also shown to be closely located to human mutation sites
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associated with mitochondrial encephalopathy (Elo, Yadavalli et al. 2012).
Recently, reports of mitochondrial tRNA mutations were observed in a Chinese
population with essential hypertension (Li, Liu et al. 2009; Liu, Li et al. 2009).
Additionally, Wilson et al. (2004) describe a causal relationship between a
T4921C transition SNP, which lies in the mitochondrial tRNAlle gene and
hypertension. The genetic association of mtDNA variants and tRNA mutations to
type 2 diabetes and hypertension directly implicated mitochondrial defects to the
etiology of cardiovascular disease and metabolic syndrome (Wallace 2005).
Taken together, there is significant evidence of mtDNA mutations and altered
mitochondrial

genetic

expression

that

may

play

a

significant

role

in

cardiovascular disease phenotypes.

The viability of individual electron transport chain (ETC) subunits and the
potential for disease has been evaluated. Altered function of complex I has been
linked to cardiovascular disease (Antonicka, Ogilvie et al. 2003; LopezCampistrous, Hao et al. 2008). Lopez-Campistrous et al. revealed defects in
complex I in the brainstem of SHR, resulting in increased reactive oxygen
species production, decreased ATP synthesis and impaired respiration in
hypertension (Lopez-Campistrous, Hao et al. 2008). Altered function of complex
III, a major site of superoxide formation and ROS production, may play an
important role in renal mitochondrial ETC dysfunction and cardiovascular
disease. Similar to these findings, Das et al. (1990) reported that the regulation
of ATP synthase is abnormal in SHR cardiac cells, as demonstrated by the
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inability to respond to acute increases in energy demand compared to cells from
normotensive rats . Taken together, the altered function of ETC subunits derived
from decreased

kidney-specific mt-gene expression

may have

several

implications to the development of hypertension.

To date, however, it is clear that phenotypes that may arise from mtDNA
mutations are not uniform, and can be influenced by both environmental factors
as well as the nuclear genome. Only 13 of the proteins needed to assemble the
electron transport chain are coded by the mitochondrial genome. The remaining
proteins are coded by the nuclear genome and transferred to the mitochondria.
This interaction may have profound effects on disease phenotypes.

For

example, mutations in the nDNA encoded hepatocyte nuclear factor-1 alpha
(HNF-1α) are

associated

with

hypertension (Wallace 1999).

post-pubertal diabetes,

dislipidemia

and

HNF-1 is also important in regulating nDNA-

encoded mitochondrial gene expression (Wang, Maechler et al. 2000). Patients
with type II diabetes show a downregulation in the expression of nDNA encoded
mitochondrial genes associated with mitochondrial biogenesis and transcription
(Patti, Butte et al. 2003). In the SHR, the gene encoding mitochondrial coupling
factor 6 was evaluated. Osanai et al. (2001) reported that the genetic expression
and plasma concentration of coupling factor 6 was significantly higher in SHRs
compared with normotensive controls. Functional analysis suggests that it acts
as a potent endogenous vasoconstrictor as a circulating hormone, and thus a
potential factor in the propagation of hypertension. Circulating coupling factor 6
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is also elevated in human hypertensive patients compared with normotensive
subjects (Osanai, Sasaki et al. 2003). Taken together, these findings suggest
that mitochondrial dysfunction of both mitochondrial and nuclear origin may play
a significant role in the pathophysiology of arterial blood pressure regulation and
development of hypertension (Figure 1.7).

The nuclear pathway that regulates mitochondrial transcription and biogenesis is
well established (Ventura-Clapier, Garnier et al. 2008). Peroxisome proliferatoractivated receptor gamma coactivator 1 alpha (PGC-1α) plays a central role in
regulating mitochondrial content and function within cells, because of its ability to
co-activate and augment several promoters of nuclear-encoded mitochondrial
genes, as well as regulating mitochondrial transcription via the NRF-Tfam
(Nuclear respiration factor-Transcription factor A mitochondria) pathway (Figure
1.6) (Wu, Puigserver et al. 1999).

PGC-1α regulates NRF-dependent

transcription, increases expression of both mitochondrial and nuclear encoded
genes of oxidative phosphorylation and induces mitochondrial biogenesis
(Scarpulla 2002). Decreased PGC-1α expression has been shown to decrease
expression of NRF-dependent genes, leading to metabolic disturbances
characteristic of type II diabetes (Patti, Butte et al. 2003). This linear coordinated
reduction of nuclear transcription factors, that ultimately leads to decreased
mitochondrial gene transcription appears to play a role in metabolic syndrome,
however, it’s role in the development of hypertension is largely unknown.
Additionally, it has been shown that metabolic functions are controlled by PGC-
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1α in a tissue specific manner in brown fat, muscle and liver (Puigserver 2005),
however kidney regulation of PGC-1α and its effectors is unknown.

Mitochondrial dysfunction contributes to the pathophysiology of hypertension,
renal disease, as well as other cardiovascular diseases.

Significant evidence

indicates that the RAS plays a role in developing mitochondriopathy.

AngII

stimulates mitochondrial oxidant release both directly and indirectly, leading to
energy metabolism depression, and potentially modification of gene expression,
ultimately contributing to cardiovascular-related pathologies (de Cavanagh,
Inserra et al. 2007). Dikalova et. al showed that mitochondrial superoxide was
directly related to the development of hypertension, and that targeting of
mitochondrial superoxide scavenging significantly attenuates the development of
the disease (Dikalova, Bikineyeva et al. 2010). Additionally, de Cavanagh et al.
demonstrated that oxidant stress is associated with mitochondrial dysfunction in
the SHR, and that blocking AngII with losartan provided mitochondrial-antioxidant
actions that reversed mitochondrial dysfunction and renal impairment (de
Cavanagh, Toblli et al. 2006). AngII can promote mitochondrial oxidative stress
indirectly by stimulating both nitric oxide (NO) production and NAD(P)H oxidasederived superoxide, which in turn enhances peroxynitrite
Arnal et al. 1998).

formation (Pueyo,

Substantial evidence has shown that NAD(P)H oxidase

derived reactive oxygen species are important mediators of AngII signaling
(Figure 1.7) (de Cavanagh, Inserra et al. 2007). ROS has been shown to play
an important role in the physiological and pathophysiological process in the
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central nervous system, and has been linked to activation of sympathetic nerve
activity (Gao, Wang et al. 2004) . SHRs exhibit increased NAD(P)H driven O2generation in resistance and aortic vessels (Rodriguez-Iturbe, Zhan et al. 2003;
Tanito, Nakamura et al. 2004), associated with NAD(P)H oxidase subunit
overexpression and enhanced oxidase activity (Shokoji, Nishiyama et al. 2003;
Kishi, Hirooka et al. 2004). Several polymorphisms in the promoter region of the
p22phox gene have been identified in the SHR (Zalba, San Jose et al. 2001), and
an association between p22phox gene polymorphism and NAD(P)H oxidase
mediated O2- production in the vascular wall of humans with hypertension also
has been established (Moreno, San Jose et al. 2003). Additionally, increased
expression of p47phox has been reported in the renal vasculature, macula densa
and distal nephron of young SHRs, suggesting renal NAD(P)H oxidase
upregulation in kidney structures precedes development of hypertension, that
again may be related to altered RAS activity (Kishi, Hirooka et al. 2004). The
role played by angiotensin II in developing mitochondriopathy has been
advanced recently by Benigni et al. (Benigni, Corna et al. 2009). Deletion of the
Agtr-1a gene resulted in the reduced age-related cardio-renal complications,
improved mitochondrial biogenesis, and increased longevity in mice. Treatment
with antioxidants, superoxide dismutase (SOD) mimetics, and AT1r blockers
decrease vascular O2- production and attenuate development of hypertension in
the SHR and stroke-prone SHR (Park, Touyz et al. 2002; Rodriguez-Iturbe, Zhan
et al. 2003; Shokoji, Nishiyama et al. 2003).

Taken together, these findings

suggest that oxidative stress plays an important role in genetic hypertension and
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involves NAD(P)H oxidase activity that is regulated, in part, by the AT1 receptor
and possibly AT1r genetic expression.
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Figure 1.5: Mamalian mitochondrial genome. Mammalian mtDNA
encodes 37 genes, including 13 polypeptide genes, all of which
encode essential components of OXPHOS. It also encodes the
12S and 16S rRNA genes and the 22 tRNA genes required for
mitochondrial protein synthesis (Leigh-Brown, Enriquez et al.
2010).
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Figure 1.6: Nuclear-mitochondrial pathway driving mtDNA transcription
and biogenesis. This well known pathway may be regulated in a tissuespecific manner, depending on the energetic needs of that tissue.
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Figure 1.7: Proposed role of redox-dependent cross talk between
mitochondria and NADPH oxidases (NOXs) in vascular and renal
dysfunction in hypertension. CVD, cardiovascular disease; NO, nitirc oxide;
ONOO−, peroxynitrite; eNOS, endothelial NO synthase; GPx, glutathione
peroxidase, Trx2, thioredoxin 2; mCat, catalase targeted to mitochondria;
mKATP, ATP-sensitive K+ channel; ΔΨm, mitochondrial transmembrane
potential (Dikalov 2013)
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Rationale, Overall Hypothesis and Specific Aims

Primary or essential hypertension is regarded as a multi-factorial disease,
influenced by both genetic makeup and environmental conditions. Though
several (~300) genetic loci have been identified for hypertension in the rat
(Hilbert, Lindpaintner et al. 1991; Schork, Krieger et al. 1995; Laulederkind,
Hayman et al. 2013), the exact form of the underlying genetic mechanism
remains unanswered. In addition to being polygenic, hypertension is thought to
be polygenomic, with significant evidence supporting the relationship between
mtDNA dysfunction and cardiovascular disease (Wilson, Hariri et al. 2004; de
Cavanagh, Inserra et al. 2007; Chan, Wu et al. 2009). Additionally, significant
data from our lab and others have documented that angiotensin II and the reninangiotensin system play a critical role in maintenance of arterial blood pressure
and, that this hormonal system is elevated in several experimental models of
hypertension, as well as human essential hypertension. Presented in this body
of work is evidence of renal intrinsic and extrinsic mechanisms, including specific
humoral, genetic and genomic mechanisms that appear to play a role in the
manifestation and maintenance of spontaneous hypertension. This work will be
laid out in the following aims:

Specific Aim 1 established a unique rodent colony (BN/SHR-mtSHR)
to attempt to isolate nuclear and mitochondrial genes, and their potential
interaction with the renin-angiotensin system that may be causal to
hypertension in BN/SHR-mtSHR
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Specific Aim 2 determined tissue angiotensin II, type 1 receptor
(AT1r) gene and protein expression in normotensive (NT) and hypertensive
(HT) BN/SHR-mtSHR.
•
•

Evaluate tissue-specific Agtr1a mRNA expression and incidence
of hypertension in BN/SHR-mtSHR
Evaluate kidney- and hypothalamic- specific AT1 protein
expression and incidence of hypertension in BN/SHR-mtSHR

Specific Aim 3 evaluated sodium sensitivity and renal function in
hypertensive and normotensive BC5 sibxsib BN/SHR-mtSHR.
•

Characterize renal function, pressure-natriuresis and diuresis in
normotensive and hypertensive BN/SHR-mtSHR

Specific Aim 4 evaluated tissue-specific nuclear and mitochondrial
genes involved in oxidative phosphorylation and their role in spontaneous
hypertension in BN/SHR-mtSHR.
•
•
•

Evaluate tissue-specific mitochondrial gene expression and
incidence of hypertension in BN/SHR-mtSHR
Evaluate tissue-specific gene expression of nuclear regulatory
factors for mitochondrial transcription and regulation
Characterize kidney-specific OXPHOS using cytochrome
oxidase staining in normotensive and hypertensive BN/SHRmtSHR

Copyright © Jason Andrieu Collett 2014
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CHAPTER 2
SPONTANEOUS HYPERTENSION: THE SPONTANEOUSLY HYPERTENSIVE
RAT & DEVELOPMENT OF BN/SHR-mtSHR CONPLASTIC RAT MODEL

Jason Andrieu Collett, Jeffrey L. Osborn

Abbreviations used: BN, Brown Norway rat; WKY, Wistar Kyoto rat; SAP,
systolic arterial pressure

Keywords: Spontaneous hypertension, heritable hypertension, Spontaneously
Hypertensive Rat, conplastic breeding
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2.1 Introduction: Development of the Spontaneously Hypertensive Rat

The various mechanisms underlying human hypertension have been difficult to
study as there is individual variation in the polygenetic/polygenomic disposition
and environmental factors that are difficult to differentiate from each other. The
most commonly used model of experimental hypertension is the Spontaneously
Hypertensive rat (SHR). Okamoto-Aoki SHRs are descendants of an outbred
Wistar male (WKY) with spontaneous hypertension from a colony in Kyoto,
Japan (Okamoto and Aoki 1963). Briefly, A male rat with spontaneously high
systolic blood pressures of 150 to 175 mmHg persisting for more than one month
and a female rat with elevated systolic blood pressures (130 to 140 mmHg), were
mated to obtain F1 rats. Of these F1 rats, males and females with hypertension,
as defined as systolic BP > 150mmHg persisting for more than a month were
mated to produce F2 generation rats. The procedure was repeated to obtain F3,
F4, F5 and F6 rats totaling 380 animals. The incidence of the spontaneous
occurrence of hypertension increased, and the development of hypertension
occurred at younger ages from generation to generation.

The incidence of

severe hypertension (SYS>200mmHg) increased with each generation, so that
among male animals it increased from only 9% in F2 to 35% in F3, 42% in F4,
and 56% in F5, and in female animals from 3% in F2, 16% in F3, 33% in F4, and
37% in F5 (Okamoto and Aoki 1963). From 1968, this inbred strain of SHRs was
further developed in the USA and elsewhere (Kurtz and Morris 1987). The
various colonies of SHR are pre-hypertensive for the first 6–8 weeks of their lives
with systolic blood pressures around 100–120 mmHg (Adams, Bobik et al. 1989),
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and then hypertension develops over the next 12–14 weeks(Doggrell and Brown
1998). As in humans, hypertension develops more rapidly and becomes more
severe in male than female SHR (Iams and Wexler 1979). In vivo studies have
shown that, in the early stages of hypertension, SHRs have an increased cardiac
output with normal total peripheral resistance. As the SHR progresses into the
established hypertension state, the cardiac output returns to normal and the
hypertrophied blood vessels produce an increase in the total peripheral
resistance.

Researchers in hypertension have commonly used SHRs which have, within
each colony, uniform polygenetic disposition that influence the cardiovascular
system. It was, and continues to be the hope of geneticists and physiologists
that the SHR will be pivotal in identifying genes contributing significantly to the
pathophysiology of hypertension. The nuclear loci causal to chronic elevated
arterial pressure have been extensively investigated in the SHR (Kurtz, Casto et
al. 1990; Ye and West 2003; Atanur, Birol et al. 2010; Pravenec and Kurtz 2010;
Yamamoto, Okuzaki et al. 2013). Translationally, the SHR follows the same
progression of hypertension as human hypertension with pre-hypertensive,
developing and sustained hypertensive phases with each phase lasting at least
several weeks (Folkow 1993). However, the SHR differs from human
hypertension in that SHRs reproducibly develop hypertension in young adulthood
rather than in middle age as in humans. SHRs have a defined “pre-hypertensive
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state”, which makes the model invaluable to be used in studies of the cause and
development of hypertension.

The WKY controls were established later, in 1971, as a normotensive control
strain by the National Institutes of Health (USA) as an inbreed of the Wistar
Kyoto colony via brother×sister mating (Kurtz and Morris 1987). The degree of
genetic difference between the SHR and WKY strains and within different
colonies of each strain is substantial and comparable to the extreme variability
that exists between human populations and thus unlikely to be related solely to
hypertension (Johnson, Ely et al. 1992; St Lezin, Simonet et al. 1992).
Differences between SHRs and Wistar normotensive rats other than WKY may
be more likely to be hypertension-related than differences between SHR and
WKY because the SHRs were derived from the WKY, hypertension may develop
spontaneously in the WKY, and the WKY may share some of the genes
responsible for hypertension with the SHR (Louis and Howes 1990).

The SHR has been shown to exhibit lower blood pressure when administered the
most common antihypertensive medications (Pinto, Paul et al. 1998). Thus, it is
not surprising that SHRs have been used extensively and successfully for 50
years to test compounds for their effectiveness in lowering blood pressure, and to
study the mechanisms of established hypertension.
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To investigate mechanisms underlying spontaneous hypertension, we utilized the
Okamoto-Aoki SHR in a unique breeding paradigm to isolate nuclear and
mitochondrial genes responsible for the manifestation of heritable hypertension.
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2.2 Development of BN/SHR-mtSHR “conplastic” rat model for investigating
physiological and genetic mechanisms of spontaneous hypertension

Hypertension in the Okamoto-Aoki SHR is both neurogenic and genetic in nature.
The present study measured the arterial blood pressures of offspring over six
generations (F1-BC5) of breeding in a “conplastic” colony derived from mating a
female hypertensive, SHR with a systolic arterial pressure (SAP) averaging 188
mmHg with two normotensive Brown Norway (BN) males (SAP 100 & 104
mmHg, respectively).

Hypertension was defined in all offspring as a SAP ≥

145mmHg, normotension as SAP ≤ 124mmHg and borderline hypertension as
125mmHg < SAP < 145mmHg.

F1 – BC5 female offspring with a SAP ≥

145mmHg were back bred to the original, normotensive, founder BN males
(Figure 2.1). Offspring at each generation were raised to adulthood and blood
pressure measurements were obtained by tail cuff plethysmography at 8, 12, and
16 weeks of age, as well as into later adulthood ages. The purpose of this
breeding paradigm was two-fold. First, hypertensive nuclear “loci” that are likely
causal to hypertension were isolated on a normotensive, Brown Norway
background. Second, as females were phenotypically selected for back breeding
at each generation, all offspring of the colony had identical mitochondrial
genomes of the founder SHR hypertensive female.

This breeding paradigm

allowed for the investigation of any potential role that the mitochondria may play
in the development and maintenance of the inherited hypertension.

Six

generations produced more HT (n=88; 46%) than NT (n=21;11%) offspring,
documenting consistent and dominant expression of the hypertensive phenotype.
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These results indicate that dominant alleles of both the nuclear and mitochondrial
genomes may be responsible for the development of hypertension in rats with a
decreasing SHR nuclear genome that is replaced with a Brown Norway genome.

2.2.1 Methods and Materials

Rats were raised in a 12 hr light: 12 hr dark cycle in a climate at 20° to 22°C from
birth. At 3 weeks of age, rats were weaned and transferred to either individual
(males) or group (≤3 females of the same litter) solid-wall cages with bedding
and were provided a commercial standard rodent chow and tap water ad libitum.
Beginning at 10 weeks of age, rats were phenotyped as normotensive, borderline
hypertensive or hypertensive using tail cuff plethysmography (Kent Scientific,
Torrington, CT). Hypertensive female offspring were then back-crossed to the
original progenitor BN males for 5 subsequent generations. All rats in the colony
possessed identical mitochondrial genomes, with increasing BN nuclear genome
with each subsequent backcross generation.

After repeated blood pressure

recordings that assured consistent determination of adult arterial pressure, rats
were euthanized with an overdose of sodium pentobarbital (60 mg/kg i.p).,
immediately decapitated, and organ tissues were rapidly frozen in a solution of
dry ice and acetone.
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2.2.2 Measurement of arterial pressure.

Since animals were to be back-bred to the founder males in the establishment of
the conplastic genome, tail cuff plethysmography was used as a phenotyping
methodology only to establish basic individual blood pressures. To minimize
stress and improve reliability of blood pressure measurements, several steps
were used in the blood pressure recording method that has been previously
characterized and published (Kurtz, Griffin et al. 2005). Rats were exposed and
acclimated to the measurement procedures and restraint equipment prior to BP
recordings. A dark cover was placed over the restrained animal for the duration
of the BP measurement, and BP recordings were performed at the same time
each day. All equipment was thoroughly cleaned and disinfected before and
after each individual rat to eliminate foreign scent. Animals were moderately
warmed to dilate the ventral artery. Arterial pressures were derived from the
average results of ≥5 measurements in each recording session. The average
blood pressures of ≥5mmHg separate recording sessions with <5% variability
were used to establish the phenotype of each animal. Both systolic and diastolic
pressures were obtained and recorded. For purposes of reporting, the systolic
pressures were used for the determination of the specific individual phenotype.
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2.3 Results

Progenitor female SHR had a SAP of 188mmHg and progenitor BN males had
SAPs of 100 (BN*) and 104 (BN^) mmHg. The BN*/SHR-mtSHR produced six
generations, yielding 94 total offspring, with 42.6% (n=40) expressing the
hypertensive phenotype, 42.6% (n=40) expressing the BHT phenotype, and only
14.9% (n=14) expressing the normotensive phenotype (Table 2.1). The
BN^/SHR cross/backcross also produced six generations, yielding 71 total
offspring, with 52.1% (n=37) expressing the hypertensive phenotype, 39.4%
(n=28) expressing the BHT phenotype, and only 8.5% (n=7) expressing the
normotensive phenotype (Table 2.2). Together, the 6 total generations produced
190 offspring, with 110 (58%) female and 80 (42%) male offspring. There were
significantly more hypertensive (n=88; 46%) than normotensive offspring
(n=21;11%), while a large number of individuals expressed the intermediate
phenotype (n=81; 43%). There were no differences in SAP between male and
female offspring at any generation.

Furthermore, comparison of systolic,

diastolic and mean arterial pressures of male and female offspring across all
backcross generations did not demonstrate any gender differences in arterial
pressures. Hypertension was dominantly expressed and maintained across all
six offspring generations of BN/SHR-mtSHR rats (Figure 2.2).

With the conplastic breeding paradigm, the BN contribution to the nuclear
genome at each generation is as follows: F1: 50%, BC1: 75%, BC2: 87.5%, BC3:
93.75%, BC4: 96.875%, BC5: 98.4375%. Thus, at the 6th generation, SHR only
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accounts for 1.5625% of the nuclear genome, however, the hypertensive
phenotype is still dominantly expressed (Figure 2.2).

Additionally, the

mitochondrial genomes of all offspring (n=190), barring any mutations, are
identical to the founder SHR female.
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2.4 Implications and Significance

Because of the lack of appropriate animal models, the potentially causal
contributions of inherited mitochondrial genomic factors to complex traits are less
well studied compared with inherited nuclear genomic factors. To evaluate the
effects of these mtDNA variations in the absence of the corresponding nuclear
genomic factors as confounding variables, novel conplastic BN/SHR-mtSHR rats
were constructed using a founder male back breeding paradigm and
characterized for the existence of hypertension.

Utilizing this unique rodent

colony, one can begin to understand the different roles that the nuclear and
mitochondrial genome may be playing in the development of chronic elevated
arterial pressure, and subsequently the development of cardiovascular disease
associated with arterial hypertension.
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Figure 2.1: Breeding paradigm for BN/SHR-mtSHR rats. Hypertensive
female SHR (SAP= 188mmg) was crossed with two BN males (100mmHg*
and 104mmHg^ respectively). Back-breeding female offspring using
phenotypic selection of elevated arterial pressure (>145mmHg) was used to
provide the second generation (BC1). Subsequent back-crossing was
performed for five additional generations to create 6 total generations (F1,
BC1-BC5).
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Figure 2.2: Six generations of BN/SHR-mtSHR rats with
corresponding average systolic pressure (SAP) values. The Po
generation represents repeated measures of the founding SHR and
BNs. Each individual dot in generations F1-BC5 represent average
BP of individual rats. Three distinct populations persisted throughout
all 6 generations (NT animals above red dotted line, NT animals
below green dotted line, and BHT animals between red and green
dotted lines), with hypertension being dominantly expressed and
maintained. Modified from (Collett, Hart et al. 2013)
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Table 2.1: Phenotypic characterization of BN*/SHR-mtSHR colony. Phenotypes
are separated according to gender. There was no difference in SAP between
genders. SAP values are expressed as mean ± S.E.M.
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Table 2.2: Phenotypic characterization of BN^/SHR-mtSHR colony. Phenotypes
are separated according to gender. There was no difference in SAPs between
genderss. SAP values are expressed as mean ± S.E.M

Copyright © Jason Andrieu Collett 2014
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3.1 Introduction

Hypertension and the chronic elevation of blood pressure constitute a primary
and significant factor in the development of cardiovascular disease. Essential
hypertension is regarded as a multi-factorial disease, influenced by both genetic
makeup and environmental conditions that can alter genomic expression
(National Heart, Institute et al. 1977), (Raizada, Sumners et al. 1993), (Schork,
Krieger et al. 1995). The polygenic nature of hypertension and its dependence
on environmental factors complicate the clear identification of genetic factors that
directly increase blood pressure (Joe and Garrett 2005).

The rat is a well-

established animal model for investigating human hypertension, with over 25,000
papers reported on hypertension in rats alone (Kwitek-Black and Jacob 2001).
Rat models of spontaneous hypertension, in particular, the SHR, have been
critical to our understanding of blood pressure control and the pathophysiology of
hypertension. Significant progress has been made to map the genes involved in
blood pressure regulation in these animal models. Nuclear and mitochondrial
genome scans have been carried out in rats, mice and humans and have
revealed several potential genomic regions that may contain genes involved in
the pathogenesis of spontaneous hypertension (Rapp 2000). Molecular genetic
analysis proves that BP regulation is polygenic, and there is good evidence for
several BP related quantitative trait loci (QTLs) on nearly every rat chromosome
(Deng, Dene et al. 1994), (Doris 2002), (Hilbert, Lindpaintner et al. 1991),
(Hopkins and Hunt 2003), (Rapp, Dene et al. 1994), (Schork, Krieger et al. 1995).
Linkage analyses of populations derived from the SHR shows potential BP QTLs
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at numerous loci, however, the precise nature of the genetic mechanisms
underlying essential hypertension remains unanswered.

Significant data from our lab and others have documented that angiotensin II and
the renin-angiotensin system play a critical role in maintenance of arterial blood
pressure and that this hormonal system is elevated in several experimental
models of hypertension, as well as human essential hypertension (Cowley 1992),
(de Gasparo, Catt et al. 2000), (Doris 2002), (Lenkei, Palkovits et al. 1997),
(Lifton, Gharavi et al. 2001), (Reinhart, Lohmeier et al. 1995), (Weir and Dzau
1999).

It has been suggested that the renin-angiotensin system RAS plays a

pathogenic role in the development of hypertension in Aoki-Okamoto SHR. An
elevated RAS impacts blood pressure directly via vasoconstriction and sodium
retention, as well as indirectly, through increased reactive oxygen species,
altering redox signaling and increased sympathetic outflow.
Here we demonstrate a unique rat colony developed by breeding a hypertensive
female Okamoto-Aoki SHR with male, normotensive Brown Norway (BN) rats.
Hypertensive female offspring were backcrossed with the original males for 5
subsequent generations.

Despite the dilution of the “hypertensive” nuclear

genome, hypertensive phenotype expressed by the founder female was
dominantly expressed and maintained across 6 generations of BN/SHR-mtSHR
rats.

All progeny however, have identical mitochondrial genomes.

We

investigated the tissue-specific mRNA expression of the RAS pathway, including
angiotensinogen (AGT), renin (REN), angiotensin converting enzyme 1 (ACE1),
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angiotensin converting enzyme 2 (ACE2) and angiotensin II, type 1 receptors
(Agtr1a) in normotensive and hypertensive BN/SHR-mtSHR backcross rats. It is
hypothesized that tissue-specific increased RAS expression contributes to
heritable hypertension in BN/SHR-mtSHR rats.
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3.2 Materials and Methods

3.2.1 Animals.

All experiments were carried out in accordance with the AAALAC Guide to the
Care and Use of Laboratory Animals and all protocols were previously approved
by the University of Kentucky Institutional Animal Care and Use Committee (UK
IACUC). A congenic colony using phenotypic selection was employed. The
Aoki-Okamoto SHR/Brown Norway (BN/SHR-mtSHR) rat colony was developed by
breeding a female SHR (Charles River Labs, Wilmington, MA) with 2 different
normotensive Brown Norway males (BN* and BN^, respectively; Charles River
Labs, Wilmington, MA). Rats were raised in a 12 hr light: 12 hr dark cycle in a
climate at 20° to 22°C from birth. At 3 weeks of age, rats were weaned and
transferred to either individual (males) or group (≤3 females of the same litter)
solid-wall cages with bedding and were provided a commercial standard rodent
chow and tap water ad libitum.

Beginning at 10 weeks of age, rats were

phenotyped as normotensive, borderline hypertensive or hypertensive using tail
cuff plethysmography (Kent Scientific, Torrington, CT).

Hypertensive female

offspring were then back-crossed to the original progenitor BN males for 5
subsequent generations. All rats in the colony possessed identical mitochondrial
genomes, with increasing BN nuclear genome with each subsequent backcross
generation. After repeated blood pressure recordings that assured consistent
determination of adult arterial pressure, rats were euthanized with an overdose of
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sodium pentobarbital (60 mg/kg i.p)., immediately decapitated, and organ tissues
were rapidly frozen in a solution of dry ice and acetone.
Brains were carefully removed from the skull, and hypothalami were excised
using previously characterized specific landmarks:

anterior – optic chiasm;

lateral – optic nerve projections; dorsal – fornix.
Age and sex matched HT (N=20) and NT (N=20) animals across 6 generations of
BN/SHR-mtSHR were chosen for RAS mRNA evaluation.

Animals in the

backcross generation 3 (BC3) were chosen for protein analysis as there were an
appropriate number of age and sex matched NT and HT rats within a single
generation.

3.2.2 Measurement of Arterial pressure.

Systolic arterial pressure (SAP) was evaluated in parents and offspring beginning
at 10-12 weeks of age. Phenotypes were assigned as either normotensive (NT:
SAP ≤ 124mmHg), borderline hypertensive (BHT: 125 ≤ SAP < 145 mmHg) or
hypertensive (HT: SAP ≥ 145mmHg). Since animals were to be back-bred to the
founder males in the establishment of the conplastic genome, tail cuff
plethysmography was used as a phenotyping methodology only to establish
basic individual blood pressures. To minimize stress and improve reliability of
blood pressure measurements, several steps were used in the blood pressure
recording method that has been previously characterized and published (Kurtz,
Griffin et al. 2005). Rats were exposed and acclimated to the measurement
procedures and restraint equipment prior to BP recordings. A dark cover was
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placed over the restrained animal for the duration of the BP measurement, and
BP recordings were performed at the same time each day. All equipment was
thoroughly cleaned and disinfected before and after each individual rat to
eliminate foreign scent. Animals were moderately warmed to dilate the ventral
artery.

Arterial pressures was derived from the average results of ≥5

measurements in each recording session.

The average blood pressures of

≥5mmHg separate recording sessions with <5% variability were used to establish
the phenotype of each animal.

Both systolic and diastolic pressures were

obtained and recorded. For purposes of reporting, the systolic pressures were
used for the determination of the specific individual phenotype.

3.2.3 RNA Extraction and RT-PCR.

Kidney, liver and lung tissue were harvested from HT and NT rats (n=20 NT;
n=20 HT) as described above.

Total RNA was extracted by Trizol reagent

(Invitrogen, Carlsbad, CA) and purified using RNeasy minicolumns (Qiagen Inc.,
Valencia, CA) according to manufacturer’s protocol. Possible genomic DNA in
total RNAs was digested with RNA-free DNase I (Qiagen Inc., Valencia, CA).
Concentration and purity of all RNA samples was determined by the Nanodrop
ND-1000

spectrophotometer

(Nanodrop

Technologies,

Wilmington,

DE).

Extracted RNA was reverse-transcribed into complementary DNA (cDNA) using
qScript cDNA supermix (Quanta Biosciences, Gaithersburg, MD) in a total
volume of 20µl using a MyCyler Thermal Cycler (Bio-Rad Laboratories, Hercules,
CA).
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3.2.4 Quantitative Real-Time PCR.

Quantitative Real-Time PCR was performed on a StepOnePlus Real-time PCR
system (Applied Biosystems). Real-time quantitative PCR amplifications were
performed in triplicate in a 96-well plate. For normalization, GAPDH was used as
the reference gene.

Pre-designed primers and hydrolysis probes were

purchased from Integrated DNA Technologies, Inc.

(Agtr1a; Primer 1: 5’-

CCAGCCATTTTATACCAATCTC-3’, Primer 2: 5’-TCCTGTTCCACCCGATCA-3’,
Probe:

5’-/HEX/CAGCTCTGC/ZEN/CACATTCCCTGAGT/

(GAPDH;

Primer

1:

5’GTAACCAGGCGTCCGATAC-3’,

GTTCTAGAGACAGCCGCATC-3’,
CACCGACCTTCACC/3IABkFQ/-3’.)

Probe:

3IABkFQ/-3’.)
Primer

2:

5’-

5’-/56-FAM/ATCCGTTCA/ZEN/

Pre-designed

TaqMan

primers

and

hydrolysis probes for AGT (Rn00593114_m1), REN (Rn00561847_m1), ACE1
(Rn00561094_m1), ACE2

(Rn01416293_m1) were

purchased from

Life

Technologies.

Relative gene expression was calculated using the comparative

CT method.

Primers and probes were verified and operating at similar

efficiencies.

3.2.5 Membrane Protein Extraction.

Whole kidney and hypothalamic tissues were placed in an ice-cold buffer solution
containing 1M Tris, 5M NaCl, 0.5M EDTA, 100% Brij 96/97 and 10% NP40 with
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0.3% protease inhibitor leupeptin (50μM), aprotinin (50nM) and pepstatin (1μM).
Tissue samples were immediately homogenized (PowerGen® 125 Homogenizer,
Fisher Scientific, Pittsburgh, PA) at 4°C for approximately 15 seconds. After
complete homogenation, samples were loaded into a centrifuge (Heraeus
Biofuge 13, Baxter Scientific, Deerfield, IL) and spun at 13,000 rpm for 10
minutes at 4°C. Protein concentration was determined for each sample using
colorimetric assay according to Lowry et al. (Lowry, Rosebrough et al. 1951).

3.2.6 Western blot analysis of AT1 Receptor.

Kidney and hypothalamic protein samples were electrophoretically separated on
4% to 10% SDS-Page gels at 150V/50mA for 1 hour.

Separated proteins were

transferred by electroelution (200V, 1-2hrs) to polyvinylidene difluoride (PVDF)
membranes (0.45μm;Millipore, Bedford, MA). Molecular weight markers (~10190kDa; Benchmark Prestained Protein Ladder, Invitrogen, Carlsbad, CA) were
used to estimate molecular mass. Blots were blocked with 5% bovine serum
albumin (BSA) in Tris-buffered saline.

Blots were incubated with primary

antibodies AT1r (1:200, sc-81671) and β-tubulin (loading control; 1:200, sc23949; Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 25°C for 2 hours.
Blots were washed with Tris-buffered saline/0.1% Tween-20 (TBST) and then
exposed to secondary antibody conjugated to horseradish-peroxidase (1:2000,
sc-2005; Santa Cruz, CA) at 25°C for 2 hours. Detection of specific proteins was
accomplished using enhanced chemiluminescence (SuperSignal West Pico,
Thermo Scientific, Rockford, IL) according to manufacturer’s instructions, and
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blots were exposed to BioMax Light Autoradiography film (Kodak #1788207).
Densitometric results were reported as integrated values (area density of band)
and expressed as a ratio of AT1r to loading control (β-tubulin). Results were then
compared between phenotypic groups. Lanes lacking protein were subject to
AT1r and β-tubulin primary antibody to verify antibody selectivity. Densitometry
reflects mean ± S.EM. of all samples.

3.2.7 Statistical analysis.

Blood pressures, as well as tissue AT1r protein expression between NT and HT
BN/SHR-mtSHR rats were analyzed using an Student’s T-test. Renal AGT, REN,
ACE1, ACE2 and Agtr1a mRNA expression levels between HT and NT BN/SHRmtSHR rats were analyzed using Mann-Whitney U Test comparisons. The 0.05
level of probability was utilized as the criterion of significance.

All statistical

analyses were performed using GraphPad Prism 4 (GraphPad Software, Inc., La
Jolla, CA).
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3.3 Results

3.3.1 Arterial pressure phenotyping of BN/SHR-mtSHR colony.

Systolic arterial pressure phenotypes were assessed weekly beginning at 10-12
weeks of age according to the following arterial blood pressure parameters:
normotensive

(NT:

SAP

≤

124mmHg),

borderline

hypertensive

(BHT:

125mmHg<SAP< 145 mmHg) or hypertensive (HT: SAP > 145mmHg).
Progenitor female SHR had a SAP of 188mmHg and progenitor BN males had
SAPs of 105 (BN*) and 103 (BN^) mmHg. The BN*/SHR-mtSHR cross/backcross
produced six generations, yielding 94 total offspring, with 42.6% (n=40)
expressing the hypertensive phenotype, 42.6% (n=40) expressing the BHT
phenotype, and only 14.9% (n=14) expressing the normotensive phenotype. The
BN^/SHR-mtSHR cross/backcross also produced six generations, yielding 71 total
offspring, with 52.1% (n=37) expressing the hypertensive phenotype, 39.4%
(n=28) expressing the BHT phenotype, and only 8.5% (n=6) expressing the
normotensive phenotype.

Together, the 6 total generations produced 190

offspring, with 110 (58%) female and 80 (42%) male offspring.

There were

significantly more hypertensive (n=88; 46%) than normotensive offspring
(n=21;11%), while a large number of individuals expressed the intermediate
phenotype (n=81; 43%). There were no differences in SAP between male and
female offspring at any generation.

Furthermore, comparison of systolic,

diastolic and mean arterial pressures of male and female offspring across all
backcross generations did not demonstrate any gender differences in arterial
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pressures. Hypertension was dominantly expressed and maintained across all
six offspring generations of BN/SHR-mtSHR rats (Figure 3.1).

3.3.2 Renal Agtr1a mRNA expression is higher in hypertensive BN/SHR than in
normotensive BN/SHR-mtSHR rats.

The mRNA levels of AGT, REN, ACE1 and ACE2 and Agtr1a in renal tissue were
evaluated NT and HT BC3 (NT: n=6, HT: n=6; Figure 3.2) and in HT and NT rats
representative of each generation of BN/SHR-mtSHR rats (n=20 NT; n=20 HT;
Figure 3.3). Animals exhibiting the most extreme phenotypes were chosen for
mRNA expression analysis. AGT, REN, ACE1 and ACE2 mRNA levels were not
different between NT and HT BN/SHR-mtSHR rats. Renal Agtr1a was increased
by ~2.5-fold (P < 0.05) in HT compared to NT BN/SHR-mtSHR rats (Figure 3.2).
Expression is reported as relative expression using 2-ΔΔCT method.

NT values

were normalized to 1.

3.3.3 Systemic RAS mRNA expression is not different in hypertensive compared
to normotensive BN/SHR-mtSHR rats.

The mRNA levels of liver AGT, Agtr1a and lung ACE1 were evaluated in HT and
NT BN/SHR-mtSHR rats (n=20 NT; n=20 HT).

Animals exhibiting the most

extreme phenotypes were chosen for mRNA expression analysis. Liver AGT,
Atgr1a and lung ACE1 mRNA levels were not different between NT and HT
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BN/SHR-mtSHR rats (Figure 3.4 A,B,C).

Expression is reported as relative

expression using 2-ΔΔCT method. NT values were normalized to 1.

3.3.4 Renal AT1 receptor protein expression is higher in hypertensive BN/SHRmtSHR than in normotensive BN/SHR-mtSHR rats.

Western blot analysis of AT1 receptor protein from whole kidney homogenates
using the monoclonal antibody showed that AT1 receptor protein levels were
significantly higher (p<0.05; Figure 3.5A) in BC3 HT rats compared to NT rats.
The ratio of renal AT1 to β-tubulin densitometric signals were 1.000 ± 0.097 vs.
1.379 ± 0.06975 (Figure 3.5B).

Regression analysis was also performed,

indicating a positive correlation (r2=0.6502, p<0.05) between SAP and AT1
receptor protein expression in kidney of BC3 BN/SHR-mtSHR rats (Figure 3.5C).

3.3.5 Hypothalamic AT1 receptor expression is higher in hypertensive BN/SHRmtSHR than in normotensive BN/SHR-mtSHR rats.

Western blot analysis of AT1 receptor protein from hypothalamus homogenates
using the same monoclonal antibody showed that AT1 receptor protein levels
were significantly higher (p<0.05) in BC3 HT rats compared to NT rats (Figure
3.6A). The ratio of hypothalamic AT1 to β-tubulin was 2.600 ± 0.07616 (NT:
N=16) vs. 3.072 ± 0.2031 (HT: N=18) respectively (Figure 3.6B). Regression
analysis was also performed, indicating a positive correlation (r2=0.4781, p<0.05)
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between SAP and AT1 receptor protein expression in hypothalamus of BC3
BN/SHR-mtSHR rats (Figure 3.6C).
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3.4 Discussion

The main findings of this study are: 1) elevated arterial pressure is dominant and
maintained across 6 generations of BN/SHR-mtSHR rats, despite the increasing
nuclear genomic contribution of the NT male donor rats, 2) hypertensive
BN/SHR-mtSHR rats across 6 generations exhibit elevated renal Agtr1a mRNA
expression compared to NT BN/SHR-mtSHR rats, while expression of renal REN,
liver AGT and Agtr1a and lung ACE1 were not different 3) hypertensive BN/SHRmtSHR in the BC3 generation exhibit an elevated AT1r protein expression in
kidney and hypothalamus compared to NT BN/SHR-mtSHR rats, 4) increased AT1r
expression is positively correlated with elevated SAP in BC3 BN/SHR-mtSHR rats.
Taken together, these results suggest that hypertension is dominant in the
presence of increasing normotenive “loci” and that tissue-specific altered
expression of AT1r, but not other aspects of renal or systemic RAS, may underlie
heritable hypertension.

The SHR has been the most widely studied genetic model of essential
hypertension in the past four decades (Pinto, Paul et al. 1998). Neurogenic in
nature, the underlying mechanisms of the onset and manifestation of
hypertension in the SHR remains to be fully elucidated. In this experimental
paradigm, an attempt to isolate genomic regions from which hypertension derives
in a “conplastic” colony using phenotypic selection was employed. In these rats,
the nuclear genome of the 6th generation (BC5) offspring is comprised of ~96.9%
original BN males, and only 1.6% of original donor SHR.
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The dilution of the

hypertensive genome had seemingly little effect on the manifestation of the
hypertensive phenotype from generation F1 through backcross 5 (Figure 3.1). It
is clear, however, that the magnitude of the hypertension was never as high in
the offspring, as in the progenitor SHR even from the initial F1 generation. In
fact, there is approximately a 30 mmHg difference between the average SAP of
the SHR and F1 generation offspring. However, from the F1 generation forward,
the magnitude of elevated blood pressure did not decline toward the BN blood
pressure in any of the subsequent offspring generations.

Thus, although a

significantly increasing influence of the BN genome is transmitted following
genetic mixing with SHR of subsequent backcross generations, the impact of the
SHR genome was fully maintained for 6 consecutive generations (F1-BC5)
following the initial mating.

Since the discovery of “renin” in 1898 and subsequent recognition that Ang II is
pressor, the RAS has been extensively studied and remains a major candidate
as a causative factor in elevated arterial pressure and the pathogenesis of
hypertension (Carey and Siragy 2003), (de Gasparo, Catt et al. 2000),
(Tigerstedt and Bergman 1898). The angiotensin II, type 1 receptor has been
extensively evaluated in rodents and has subsequently become a target as a
causal factor in the development of essential hypertension. Reja et al. (2006)
showed that gene expression levels of AT1r, extracellular signal-regulated kinase
2 and phosphatidylinositol 3-kinase were significantly higher in the PVN, RVLM
and adrenal medulla in SHR compared to normotensive WKY rats. Raizada et al.
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(1993) showed that AT1r mRNA was higher in the brains of the SHR compared to
normotensive WKY rats.

Furthermore, Gyurko et al. (1993) showed that

antisense inhibition of AT1 receptor mRNA in the brain reduces the magnitude of
hypertension in adult SHR.

Data from our study supports the notion that

elevated AT1 receptors may play a role in SHR-derived elevated arterial
pressure. Hypertensive BN/SHR-mtSHR rats across several generations exhibit
elevated renal specific Agtr1a mRNA (Figures 3.2 and 3.3) expression while
expression of other renal RAS components, as well as liver AGT and lung ACE1
were not different (Figure 3.4).

In the BC3 generation, where the nuclear

genome of the original SHR accounts for only ~6.2%, HT rats had significantly
higher AT1r and protein expression than normotensive rats in kidney and
hypothalamic tissue (Figure 3.5 and 3.6). Furthermore, average SAP and tissue
expression of AT1r were positively correlated (Figure 3.5C and 3.6C), indicating
that tissue specific expression of AT1r expression may critically impact the
development and maintenance of SHR hypertension.

Increased AT1r protein

could potentially have drastic effects on the cardiovascular system, including the
pathogenesis of hypertension, and seems to play a role in the development of
hypertension in BN/SHR-mtSHR rats.

Ang II’s effect in the kidney would be

exacerbated, increasing proximal tubular sodium reabsorption and decreasing
renal blood flow.

In the hypothalamus, elevated AT1r expression could increase

sympathetic nervous activity and/or vasopressin secretion, subsequently
increasing vascular resistance and sodium and water retention.

The

hypothalamus is of particular interest, as it plays a major role in sympathetic
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outflow, vasopressin production and osmoregulation (Scherrer 1959). Recently,
commercially available AT1r antibodies have come under scrutiny for lack of
specificity, and therefore may lead to erroneous results (Herrera, Sparks et al.
2013). It is critical to note here, however, that the antibody used for this study
has not previously been identified as non-specific, and that our mRNA
expression data fully corroborates the protein data that AT1r expression is
elevated in kidney of BN/SHR-mtSHR backcross rats.

With the abundance of knowledge on the role of both circulating and tissue RAS
in BP control, it is hypothesized that genetic variability in one or more of the RAS
components could account for the pathogenesis of hypertension. Common
variants of the RAS genes, including those coding for angiotensinogen and
angiotensin-converting enzyme were some of the first to be associated with
altered blood pressure control (Norton, Brooksbank et al. 2010). Several linkage
analysis and genome wide association studies have been performed in both
rodents and humans in regards to RAS genes, producing variable results (Baudin
2002), (Bonnardeaux, Davies et al. 1994), (Jeunemaitre, Soubrier et al. 1992),
(Kainulainen, Perola et al. 1999), (Rigat, Hubert et al. 1990), (Rothermund and
Paul 1998), (Schmidt, Beige et al. 1997), (Tomino, Makita et al. 1999), (Zhu,
McKenzie et al. 2000). Results from our current study highlight a renal-specific
elevation of a single gene of the RAS, therefore indicating genomic
polymorphisms at this allele are not causal to the manifestation of the disease.
Gene expression and subsequent protein synthesis may be equally, if not more
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important than heritable nucleotide differences in elucidating the causes of
complex, multigenic diseases. Data from this study indicate that AT1r mRNA and
receptor protein expression may have a significantly more important role than
other aspects of RAS in heritable hypertension.

Due to the breeding paradigm (i.e. backcrossing hypertensive females with
founder males), the influence of the mitochondrial genome (female transmission)
on the pathophysiology of hypertension should be taken into consideration.
These results provide strong evidence for the dominance of loci within the SHR
genome that are highly resistant to increasing normotensive influence of the BN
genome. At present, there are few data that identify the specific genes located in
these “SHR dominant” regions. However, it is likely that these genomic regions
contain numerous blood pressure controlling gene loci (Rapp 2000), (Lowry,
Rosebrough et al. 1951), (Kaschina and Unger 2003). As hypertensive females
were phenotypically selected for backcross, all offspring (F1, BC2-BC5) should
have identical mitochondrial genomes, barring any mutation(s). Mitochondrial
dysfunction has recently been implicated in a wide variety of genetic disorders
(Taylor and Turnbull 2005), (Wallace 1999). Alterations in mitochondrial function
are observed in conjunction with the development of hypertension in rodents and
humans (Chan, Wu et al. 2009), (Kumarasamy, Gopalakrishnan et al. 2010),
(Pravenec, Hyakukoku et al. 2007). The genetic association of mtDNA variants
(Kumarasamy, Gopalakrishnan et al. 2010), (Wilson, Hariri et al. 2004) and tRNA
mutations (Kumarasamy, Gopalakrishnan et al. 2010), (Benigni, Corna et al.
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2009), (Liu, Li et al. 2009), (Pravenec, Hyakukoku et al. 2007) to type 2 diabetes
and hypertension directly implicated mitochondrial defects to the etiology of
cardiovascular disease and metabolic syndrome.

Mitochondrial integrity and

potential dysfunction is currently being evaluated in the BN/SHR-mtSHR rats.

A potentially critical avenue in investigating the underlying mechanisms of
heritable hypertension in BN/SHR-mtSHR is the relationship between the reninangiotensin system and mitochondrial dysfunction.

The role played by

angiotensin II in developing mitochondriopathy has been advanced recently by
Benigni et al. (2009)

Deletion of the Agtr1a gene resulted in the reduced age-

related cardio-renal complications, improved mitochondrial biogenesis, and
increased longevity in mice.

Additionally, treatment with antioxidants,

mitochondrial superoxide dismutase mimetics, and AT1r blockers decreased
vascular O2- production and attenuated development of hypertension in SHR
(Park, Touyz et al. 2002), (Rodriguez-Iturbe, Zhan et al. 2003), (Shokoji,
Nishiyama et al. 2003).

De Cavanagh et al. (2006) have demonstrated that

oxidative stress is associated with mitochondrial dysfunction in SHR, and that
this dysfunction is attenuated with AT1r blockade with losartan. Taken together,
there is significant evidence of mtDNA mutations and/or altered mitochondrial
genetic expression is influenced, at least in part, by the RAS, and that this
relationship may play a significant role in the development of hypertension.
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In summary, the present results indicate that hypertension is dominantly
expressed in BN/SHR-mtSHR rats, and that elevated arterial pressure is positively
correlated with the upregulation of kidney AT1r mRNA, as well as kidney and
hypothalamic AT1r protein expression, while other aspects of the local and
systemic RAS pathways are not different. It has been reported that AT1r mRNA
is regulated in a tissue-specific manner that is distinct among the other
components of the RAS, and potentially independent of changes in circulating
Ang II (Sechi, Griffin et al. 1996). Our current study supports this finding, as well
as adds insight into the heritability and expression of different aspects of RAS.
The maintenance of hypertension under conditions where the proportion of the
female progenitor SHR mitochondrial genome remains intact, nuclear genome is
continually reduced by increasing amounts of normotensive progenitor BN
genome strongly suggests a major linkage of the SHR genes to the development
of hypertension.

While the origins of this SHR derived hypertension remain

unknown, strong physiological evidence for a major neurogenic and RAS
components have been reported. Given that the maintenance of hypertension in
the F1 and subsequent backcross generations, the encoding and linkage of
hypertensive loci may be directly related to genomic components of the female
SHR mitochondrial genome.

The presence and abundance of AT1r in the kidney and hypothalamus appears
to be related to the propagation of the HT phenotype in BN/SHR-mtSHR. This
work adds to the body of evidence that quantitative variations in gene expression
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at loci encoding components of the renin-angiotensin-aldosterone system may be
genetically linked to or associated with physiological alterations in blood
pressure. Though the RAS pathway has been a major therapeutic target for
decades, understanding the heritability of expression of these targets can help
switch the focus from treatment to prevention.

The role of AT1 receptors in

individual tissues and their differential expression provides valuable information
on how personalized therapy can be used to better treat or prevent
cardiovascular disease in the future.
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Systolic Arterial Pressure distribution across
6 generations BN/SHR-mtSHR
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Figure 3.1: Six generations of BN/SHR-mtSHR rats with
corresponding average systolic pressure (SAP) values. Three
distinct populations persisted throughout all 6 generations, with
hypertension being dominantly expressed and maintained despite the
reduction of the SHR nuclear genome. HT animals used are
indicated by the red circle. NT animals used are indicated by the
blue circle.
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Figure 3.2: Quantitative Real-Time PCR of renal AGT,
REN, ACE1, ACE2 and Agtr1a in age and sex
matched BC3 HT and NT rats. Data were normalized
to GAPDH RNA from same samples (NT n=20; HT
n=20). There was no difference in AGT, REN, ACE1
and ACE2 expression HT BC3 rats compared to NT
BC3 rats. Agtr1a mRNA levels were ~5X higher in HT
rats compared to NT rats.
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Figure 3.3: Quantitative Real-Time PCR of renal AGT, REN,
ACE1, ACE2 and Agtr1a in age and sex matched HT and NT
rats representative of all generations in the colony. Data
were normalized to GAPDH RNA from same samples (NT
n=20; HT n=20). There was no difference in AGT, REN,
ACE1 and ACE2 expression in HT compared to NT rats.
Agtr1a mRNA levels were ~2.5X higher in HT rats compared
to NT rats.
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Figure 3.4: Quantitative Real-Time PCR of liver AGT (Figure
3.4A), lung ACE1 (Figure 3.4B) and liver Agtr1a (Figure 3.4C
in BC3 HT and NT rats. Data were normalized to GAPDH RNA
from same samples (NT n=6; HT n=5). There was no
difference in liver AGT, lung ACE1 or liver Agtr1a mRNA
expression in HT BC3 rats compared to NT BC3 rats.
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Figure 3.5: Semiquantitative immunoblotting of whole kidney
tissue homogenates of BC3 HT and NT rats. A: Representative
blot of AT1r and β-tubulin. B: Illustrates quantified densitometry of
hypothalamic AT1r protein. HT rats exhibited significantly higher
AT1r protein expression compared to NT rats (p<0.05). C:
Regression analysis between SAP and AT1r protein expression in
hypothalamic homogenates. Average SAP and AT1r protein
expression were positively correlated (r2=0.6502, * = P<0.05).
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Figure 3.6: Semiquantitative immunoblotting of AT1 receptor protein
from hypothalamus homogenates of BC3 rats. A: Representative blot
comparing NT, BHT and HT AT1r densities. Β-tubulin was used as
housekeeping protein. B: Illustrates quantified densitometry of
hypothalamic AT1r protein. HT rats exhibited significantly higher AT1r
protein expression compared to NT rats (p<0.05). C: Regression
analysis between SAP and AT1r protein expression in hypothalamic
homogenates. Average SAP and AT1r protein expression were
positively correlated (r2=0.4781, * = P<0.05).
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4.1 Introduction

The relationship between dietary NaCl intake and the development of
hypertension has been the subject of much debate for several decades (Dahl
1961; MacGregor 1985; Osborn and Camara 1997).

In societies where salt

intake is less than 50 to 100 mmol/d, hypertension and cardiovascular disease
(CVD) are rare, and the frequency of hypertension and CVD increase at higher
levels of salt intake (Weinberger 1996). Pharmacological therapy with natriuretic
agents has been very successful, and is still considered a first line therapy in the
treatment of hypertension (Weinberger 1996).

However, epidemiological

observations have established profound heterogeneity between salt intake and
hypertension. There is evidence that genetic factors, particularly alterations in
genes of known osmoregulatory roles, play a very significant role in the
deleterious impact of hypertension on the progression of renal disease (Rostand,
Kirk et al. 1982). For instance, the risk of developing end-stage renal disease is
10- to 20-fold greater in black Americans than in Caucasian American patients
with essential hypertension, and this increased risk cannot readily be explained
by differences in the severity or treatment of hypertension (Rostand, Kirk et al.
1982).

One major difference is salt sensitivity.

Greater sodium retention is

thought to underlie BP determining physiology of blacks, and though the reninangiotensin system has been implicated, the exact mechanisms are currently
unknown (Tu, Eckert et al. 2014). The renin–angiotensin system, for example, is
more likely to be suppressed in blacks than in whites, consistent with greater
volume expansion from sodium accumulation and water retention (HELMER and
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JUDSON 1968; Wilson, Bayer et al. 1999). In addition, BP in blacks in contrast
to BP in whites typically increases in response to an increase in sodium intake,
i.e. greater NaCl sensitivity (Weinberger 1996). Whether blacks have a unique
renal physiology that puts them at risk for a more aggressive form of
hypertension is unclear. What is clear, is that NaCl sensitivity, or possibly the
inability to “sense” NaCl intake can have a profound effect on arterial pressure,
the pressure-diuresis-natriuresis relationship and subsequent development of
hypertension.

Like humans, genetically similar rodent models responding

differently to NaCl intake have been established. The SHR parallels the most
common form of idiopathic hypertension and that of most Caucasian Americans,
in that most SHR strains are not salt sensitive. Studies by Lundin et al. (1982) as
well as Greenberg and Osborn (1994) have shown that renal retention of sodium
in water should not be of pathogenic importance in identifying causes of
hypertension in the SHR. Still, hyperosmotic saline, as well as Ang II injected
ICV in the SHR and other rodents alters renal sodium handling and increases
BP, which may be mediated by the activation of renal sympathetic nerve activity
(Osborn and Camara 1997; Guadagnini and Gontijo 2006).

To further understand the mechanisms of sodium sensing and potential altered
renal sodium handling in rats stemming from the SHR, we utilized our unique
conplastic rodent model to evaluate acute renal responses to altered NaCl
concentrations, when rats were able to titrate their own sodium load.

It is

hypothesized that hypertensive BN/SHR-mtSHR will be unable to appropriately
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“sense” sodium load, hence ingesting more NaCl, and potentially alter renal
sodium handling compared with NT BN/SHR-mtSHR.
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4.2 Methods and Materials

4.2.1 Animals

Male rats generated from sibling-sibling crosses of a BC5 generation from the
BN/SHR-mtSHR colony described in detail previously were used for the acute
sodium intake aspect of the experiment.

All animals were maintained in

temperature controlled rooms with 12:12 h-light/dark cycle. Rats were raised
from weaning on normal NaCl chow (0.8% NaCl; Dyets, Bethlehem, PA) and
given water ad libitum.

Care of the rats before and during experimental

procedures was conducted in accordance with the policies of the National
Institutes of Health guidelines for the care and use of laboratory animals. All
protocols had received prior approval by the Institutional Animal Care and Use
Committee at the University of Kentucky.

4.2.2 Experimental Protocols

Twelve week old male rats weighing 300-400g were chosen for the experiment.
Rats were housed in metabolic pens and allowed distilled water and NaCl-free
chow ad libitum for the entirety of the 17-day experiment. Rats titrated Na+ intake
by drinking 0.9% saline for 2 acclimation days, followed by 5 experimental days.
On the fifth day, BP was measured and rats were then switched to 2.0%
hypertonic saline for 5 experimental days. On day 10, BP was measured and
rats were switched back to 0.9% saline for 5 experimental days (Figure 4.1A).
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4.2.3 Measurement of Arterial Pressure

Rats previously phenotyped as normotensive (NT: SAP ≤ 124mmHg; n=6) or
hypertensive (HT: SAP ≥ 145mmHg; n=6) were utilized for this study. Since
animals were to be back-bred to the founder males in the establishment of the
conplastic genome, tail cuff plethysmography was used as a phenotyping
methodology only to establish basic individual blood pressures. To minimize
stress and improve reliability of blood pressure measurements, several steps
were used in the blood pressure recording method that has been previously
characterized and published (Kurtz, Griffin et al. 2005). Rats were exposed and
acclimated to the measurement procedures and restraint equipment prior to BP
recordings. A dark cover was placed over the restrained animal for the duration
of the BP measurement, and BP recordings were performed at the same time
each day. All equipment was thoroughly cleaned and disinfected before and
after each individual rat to eliminate foreign scent. Animals were moderately
warmed to dilate the ventral artery. Arterial pressures were derived from the
average results of ≥5 measurements in each recording session. Both systolic
and diastolic pressures were obtained and recorded. For purposes of reporting,
the systolic pressures were used for the determination of the specific individual
phenotype.
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4.2.4 Determinations

Sodium and water intake were determined daily by weighing calibrated bottles
every 24 hours.

Sodium intake was calculated as a product of the volume

ingested and sodium concentration. Urine was collected and the volume was
determined in calibrated cylinders positioned directly under the pens. Urinary
sodium concentration was determined by flame photometry, and urinary sodium
excretion was calculated from the product of urine flow rate and sodium
concentration.

Sodium balance averaged over the experimental periods was

determined as the difference between sodium excretion and sodium intake.
Urinary protein concentration was measured by the method of Lowry et al.
(1951), and protein excretion was calculated as the product of urine flow rate and
urinary protein concentration. Bovine serum albumin was used as the standard.

4.2.5 Statistical analysis

Blood pressures, average sodium intake/excretion, water intake, sodium balance,
AT1r protein expression and urinary protein between NT and HT BN/SHR-mtSHR
rats were analyzed using an one-way ANOVA. Daily sodium intake/excretions
were analyzed using a two-way ANOVA.

The 0.05 level of probability was

utilized as the criterion of significance. All statistical analyses were performed
using GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA).
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4.3 Results

4.3.1 Arterial pressure did not change during acute sodium challenge.

SAP was significantly higher in the HT BN/SHR-mtSHR (SAP=157.0±5.2 mmHg;
n=6) compared with NT BN/SHR-mtSHR (SAP=124.2±5.5 mmHg; n=6) to begin
the study. SAP did not change (p>0.05) during any of the three phases of the
experiment (Figure 4.1B).

4.3.2 Sodium intake was maintained when offered 2.0% saline in HT while NT
BN/SHR-mtSHR decreased their sodium intake.

Average daily sodium intake for NT and HT BN/SHR-mtSHR rats is displayed in
Figure 4.2A.

Average 5-day sodium intake was significantly reduced in NT

BN/SHR-mtSHR when offered 2.0% hypertonic saline (166.3±21 to 79.554±10
µEq/day; #p<0.05), which remained suppressed when again offered 0.9% saline
(69.14±14 µEq/day;

#

p<0.05; Figure 4.2B).

HT BN/SHR-mtSHR, however,

maintained sodium intake when offered 2.0% hypertonic saline (127.5±36 to
147.9±24.9 µEq/day), that was maintained when again offered 0.9% saline
(89.7±9.8 µEq/day; Figure 4.2B). HT BN/SHR-mtSHR failed to “sense” hypertonic
saline challenge, therefore failed to reduce sodium intake (Figure 4.2B).
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4.3.3 Water intake increased in both HT and NT when offered hypertonic saline.

Average 5-day water intake was significantly increased in NT BN/SHR-mtSHR
when offered 2.0% hypertonic saline (4.2±0.37 to 11.1±0.628 ml/day; #p<0.05),
and NT rats maintained an increased water intake when again offered 0.9%
saline (9.14±0.864 ml/day;

#

p<0.05; Figure 4.3).

HT BN/SHR-mtSHR also

increased water intake when offered 2.0% hypertonic saline (5.3±1.0 to
8.9±0.231 µEq/day; #p<0.05; Figure 4.3), however water intake values were not
different in HT rats when again offered 0.9% saline (6.4±0.28 ml/day; Figure
4.3).

4.3.4 Sodium Excretion was higher in HT compared to NT BN/SHR-mtSHR.

Average daily sodium excretion for NT and HT BN/SHR-mtSHR rats is displayed in
Figure 4.4A. In accordance with elevated NaCl intake, average 5-day sodium
excretion was elevated in HT BN/SHR-mtSHR when offered 2.0% hypertonic
saline (271.7±25.1 to 331.8±31.7 µEq/day), and HT rats maintained an elevated
sodium excretion when again offered 0.9% saline (313.22±18.1 µEq/day; Figure
4.4B). NT BN/SHR-mtSHR, however, maintained sodium excretion when offered
2.0% hypertonic saline (220.5±57.7 to 229.6±52.2 µEq/day), and NT rats
maintained same sodium excretion when again offered 0.9% saline (191.3±39.4
µEq/day; Figure 4.4B). HT rats did, however, excrete more NaCl during the last
0.9% phase than NT rats (*p<0.05; Figure 4.4B).

107

4.3.5 Sodium Balance was More Negative in HT BN/SHR-mtSHR.

Cumulative daily sodium balance in illustrated in Figure 4.5A. HT rats exhibited
greater variability in maintaining sodium balance during the three experimental
phases.

Average 5-day sodium balance for NT and HT BN/SHR-mtSHR is

displayed in Figure 4.5B.

NT averaged (0.9%:-53.6±17.9 µEq/day; 2.0%:-

120.1±8.8 µEq/day; 0.9%: -122.17±7.5 µEq/day; Figure 4.5B) compared to HT
averages (0.9%: -151.0±29.2

µEq/day; 2.0%: -183.9±18.7 µEq/day; 0.9%: -

226.9±15.5 µEq/day; Figure 4.5B). HT rats exhibited greater sodium natriuresis
in all three experimental phases due to elevated arterial pressure (*p<0.05).

4.3.6 Urinary Protein Excretion was Not Different Between NT and HT BN/SHRmtSHR.

Urinary protein excretion was maintained and normal in NT and HT BN/SHRmtSHR for the entire experimental protocol. For the three experimental saline
trials, NT rats averaged (0.9%:476.7±66 µg/day; 2.0%:557.1±71 µg/day; 0.9%:
441.7±63 µg/day; Figure 4.6) compared to HT averages (0.9%: 328.2±46
µg/day; 2.0%: 413.3±62 µg/day; 0.9%: 299.7±29 µg/day; Figure 4.6). Therefore,
renal function appeared to be normal in NT and HT BN/SHR-mtSHR.
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4.4 Discussion

The necessity to maintain salt and water balance is an important aspect of land
dwelling animals.

Alterations in this balance can significantly impact

cardiovascular health and disease. Epidemiological studies have demonstrated a
positive correlation between NaCl intake and elevated blood pressure (Grim, Luft
et al. 1980; Weinberger 1996; Dahl 2005). Elevated NaCl intake may lead to the
development of hypertension and cardiovascular complications by signals
triggered by augmented extracellular [Na+] , extracellular [Cl−] , and/or osmolality
of extracellular fluids (Orlov and Mongin 2007). The present study was designed
to evaluate the influence of acute high NaCl on renal sodium handling and BP in
rats stemming from the SHR. This study is unique, in that the experimental
paradigm allowed rats to titrate their NaCl intake, providing useful information as
to the rats ability to “sense” sodium load. Both the kidney and the CNS are
involved in sodium sensing via at least two different mechanisms: Cl- and Na+
sensing in the tubular fluid and plasma osmolality in the CSF. In the kidneys,
salt-sensing and the regulation of sodium excretion is provided mainly via TGF.
TGF is triggered immediately after an elevation of salt concentration in the
tubular fluid delivered to the JGA and results in the contraction of VSMCs of
afferent arterioles, thus causing increases in the exposure of proximal tubules to
high-salt fluid via the attenuation of glomerular capillary pressure and
GFR.

CNS [Na+] sensors are primarily located in the circumventricular organs,

separate structures that line brain ventricles and consist of the SFO, MnPO, and
OVLT (Orlov and Mongin 2007). In these brain areas, the blood-brain barrier is
109

partially open due to the presence of fenestrated capillaries (Bourque and Oliet
1997; Hussy, Deleuze et al. 2000). This feature makes the circumventricular
organs an optimal location for direct sensing of the ionic composition of plasma.
SFO and OVLT may influence electrical activity of the magnocellular neurons in
the SON and PVN of the hypothalamus, both of which secrete AVP into the
circulation (Denton, McKinley et al. 1996; Hussy, Deleuze et al. 2000).
Vasopressin is produced by the magnocellular neurosecretory cells of the
hypothalamic SON and PVN, which both project to the median eminence in the
neurohypophysis. Such regulation occurs via direct excitatory projections to the
SON and PVN or indirectly via projections to the MnPO, a nucleus that also
innervates both the SON and PVN (Hussy, Deleuze et al. 2000).

Interestingly,

the PVN and SON possess their own intrinsic [NaCl]-sensing mechanism, which
adds additional complexity to the CNS regulation of salt intake and secretion.
This mechanism involves sensing changes in CSF osmolality rather than
alterations in extracellular [Na+] (Mason 1980; Oliet and Bourque 1992).

Leenen and coworkers (Budzikowski, Huang et al. 1998; Huang, Amin et al.
2006) were the first to propose that blood pressure elevation in animal models of
hypertension is triggered by augmented NaCl delivery to the CNS.

Elevated

NaCl diets may significantly affect the regulation of blood pressure and fluid and
electrolyte balance by way of changes in the sensitivity of the brain to circulating
or centrally generated humoral factors (Wilson, Bayer et al. 1999; Guadagnini
and Gontijo 2006).

For example, Andersson showed that hypertonic saline
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injected into the hypothalamus of the goat induced a large dipsogenic response
(Andersson, Dallman et al. 1969).

Additionally, when hypertonic saline is

administered into the CSF of the third ventricle, animals drink more water and
vasopressin is released from the neurohypophysis (Andersson and Olsson
1973).

Though HT BN/SHR-mtSHR were able to excrete their increased sodium

intake, results demonstrate a potential decreased ability to sense sodium load,
likely via central mechanisms in brain. Though several mechanisms could be
involved, we postulate that augmented RAS, in particular, elevated AT1r
expression may be related to the reduced sodium sensing ability in HT BN/SHRmtSHR (Figure 4.7).

It is well documented that endogenous Ang II may contribute to the development
of certain forms of experimental hypertension, including the SHR.

The

cardiovascular effects of centrally administered Ang II also may be related to
NaCl intake.

It has been reported that changes in NaCl intake may be

accompanied by changes in the density and affinity of Ang II receptors in
hypothalamic areas of the brain involved in cardiovascular, fluid, and electrolyte
regulation (Bickerton and Buckley 1961). Systemic and brain Ang II has been
shown to participate in blood pressure and salt and water balance through a
variety of mechanisms including sympathetic outflow, stimulation of vasopressin
release (Yang, Jin et al. 1992). Additionally, brain Ang II alters thirst and salt
appetite, which plays a major role in fluid and electrolyte regulation (Epstein,
Fitzsimons et al. 1970; Fluharty and Epstein 1983).
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Dukacz, et al. (2003)

previously demonstrated that long term inhibition of RAS with captopril
decreased blood pressure in the SHR, resulting in a leftward shift in the
pressure-natriuresis relationship.

This is significant, as results from our lab

demonstrate that HT BN/SHR-mtSHR have significantly more hypothalamic AT1r
protein compared with NT HT BN/SHR-mtSHR, indicating a potential relationship
between hypothalamic AT1r expression and reduced salt-sensing ability in HT
BN/SHR-mtSHR (Figure 4.7). An increase in both gene and protein expression of
renal AT1r has also been shown in HT BN/SHR-mtSHR (Collett, Hart et al. 2013).
Taken together, the presence and abundance of AT1r in the hypothalamus or
kidney is related to the HT phenotype in BN/SHR-mtSHR, and its role may be
involved in the chronic rightward shift of the renal function curve and/or a
reduced ability of sodium sensing (Figure 4.7).

The reduced ability to sense salt in HT BN/SHR-mtSHR and the compensatory
elevation of blood pressure to keep the rats in sodium balance may have
something to do with activation of renal sympathetic nerve activity. The elevated
level of efferent sympathetic tone in the SHR may alter the renal handling of
sodium and water. Renal nerve stimulation directly affects both proximal tubular
sodium reabsorption and renin release (Osborn, Holdaas et al. 1983; Chen and
Toney 2001). Greenberg et al. (2000) demonstrated the importance of the renal
nerves in mediating sodium excretion in response to sodium load in SHRs.
Camara and Osborn (2005) demonstrated that hypertension induced by chronic
left ventricular Ang II infusion is dependent upon activation of renal sympathetic
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nerve activity and is associated with sodium retention. Furthermore, Camara and
Osborn showed that lifelong increases in NaCl intake may sensitize the CNS to
low doses of Ang II, causing increases in renal sympathetic nerve activity
mediated by brain AT1r. Therefore, we postulate that lifetime desensitization of
orally ingested NaCl causes profound pressure-natriuresis that may be mediated,
in part, by activation of renal sympathetic nerves and AT1r (Figure 4.7).

In summary, we present data that demonstrate that HT BN/SHR-mtSHR have a
reduced ability to sense elevated sodium when given the option to titrate their
own NaCl load, and this may be related to tissue specific expression of AT1r
and/or elevated sympathetic nerve activity.

However, it appears that HT

BN/SHR-mtSHR have normal kidney function and are operating within normal
kidney natriuresis with increased sodium intake, which agrees with previous
studies that sodium retention is not of pathogenic importance in the SHR (Lundin,
Herlitz et al. 1982; Greenberg and Osborn 1994).

It appears then, that the

elevation of arterial pressure in SHR is important to maintain daily sodium
balance, i.e., functional pressure-natriuresis. Hence, HT BN/SHR-mtSHR is truly a
model of “essential” hypertension. It is concluded then, that long-term increases
in arterial pressure are necessary to maintain sodium balance, and that this is an
important aspect of development and maintenance of spontaneous hypertension.
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Figure 4.1: Experimental schema of the acute salt study that allowed
for rats to titrate their own salt and water. A: Illustrates the
experimental design, with three experimental phases. Rats were
given 0.9% saline for the first 5 days, followed by hypertonic 2.0% for
5 days, and then returned to 0.9% saline. Blood pressures were
taken after each of the three phases. B: Illustrates BP differences
throughout the entirely of the experiment. BP was elevated in HT
rats compared with NT rats, however, BP did not change with acute
saline challenge (p>0.05).
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Figure 4.2: Sodium intake throughout course of the experiment. A:
Illustrates the average daily sodium intake (µEq/day) for NT and HT
rats. B: Illustrates the average 5-day sodium intake for NT and HT
rats. HT rats ingested more sodium than NT rats when offered 2.0%
saline (*p<0.05), however, HT rats ingested similar amounts of sodium
in all three phases of the experiment. NT rats ingested significantly
less sodium (#p<0.05) when offered 2.0% saline, and continued to eat
less when again offered 0.9% saline.
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Figure 4.3: Average 5-day water intake (ml/day). NT rats
ingested significantly more water (#p<0.05) when offered 2.0%
saline and again offered 0.9% saline. NT rats also ingested
significantly more water than HT rats (*p<0.05). HT rats ingested
significantly more water than when offered 2.0% saline (#p<0.05),
but ingested similar amounts when again offered 0.9% saline.
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Figure 4.4: Sodium excretion throughout the course of the
experiment. A: Illustrates the average daily sodium excretion
(µEq/day) for NT and HT rats. B: Illustrates the average 5-day
sodium excretion for NT and HT rats. HT rats excreted more
sodium than NT rats when offered 2.0% saline (p>0.05),
however, this amount did not reach statistical significance until
rats were again offered 0.9% saline (*p<0.05). HT and NT rats
maintained similar amounts of sodium in all three phases of the
experiment.
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Figure 4.5: Sodium balance throughout the course of the experiment. A:
Illustrates the cumulative daily sodium balance (µEq/day) for NT and HT
rats. B: Illustrates the average 5-day sodium balance for NT and HT
rats. Both NT and HT rats were in negative sodium balance throughout
the course of the experiment, however HT rats exhibited greater
variability while maintaining elevated sodium natriuresis (*p<0.05). This
may be due to elevated arterial pressures.
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Figure 4.6: Urinary protein excretion was maintained and normal
in NT and HT BN/SHR-mtSHR for the entire experimental protocol.
Therefore, renal function appeared to be normal and not different
between NT and HT BN/SHR-mtSHR (P>0.05).
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Figure 4.7: Hypothetical pathway in which long term reduced NaCl
sensitivity could activate the RAS, increasing sympathetic nerve activity
and increases in arterial pressure. Chronic pressure-natriuresis may be
“essential” in the SHR, therefore underlie the development and
maintenance of elevated arterial pressure.

Copyright © Jason Andrieu Collett 2014
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5.1 Introduction

Hypertension constitutes a primary and significant factor in the development of
cardiovascular disease.

Despite major gains in the long-term treatment of

hypertension, cardiovascular disease remains the number one cause of death
and disability in developed countries.

Primary or essential hypertension is

regarded as a multi-factorial disease, influenced by both genetic inheritance and
environmental conditions that influence gene expression. The genetic basis of
hypertension has been focused primarily on inheritance and expression of
nuclear genes (Tsuchida, Liu et al. 1994), despite the fact that mitochondria are
present in multiple copies in each cell and have their own genome. Additionally,
and potentially of great importance, is the fact that OXPHOS depends on the
coordinated expression of two separate but interactive genomes, nuclear and
mitochondrial.

Numerous trans-factors involved with mtDNA replication,

transcription and mRNA processing are nuclear encoded, including mtRNA
polymerase, mtDNA polymerase, several regulatory transcription factors and
mtRNA processing proteins (Hein and Kobilka 1995).

This nuclear-

mitochondrial interaction is essential to cellular health and function, and therefore
may play a large role in the development of disease (Nowak 2002).

Mitochondrial dysfunction has been implicated in a wide variety of genetic
disorders (Wallace 1999; Taylor and Turnbull 2005) and alterations in
mitochondrial function have been observed in conjunction with aging and
development of hypertension in both rodents and humans (Schwartz, Duka et al.
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2004; Wallace 2005; Chan, Wu et al. 2009; Kumarasamy, Gopalakrishnan et al.
2010). Recently, mitochondrial transfer RNA (tRNA) mutations were observed in
a genetically focused population with a high incidence of essential hypertension
(Osanai, Tanaka et al. 2001; Li, Liu et al. 2009). Wilson et al. (2004) have
described a correlation between a T4921C transition SNP, which lies in the
mitochondrial

tRNAlle

gene

(GenBank

accession

no.

NC_001807)

and

hypertension. The genetic association of mtDNA variants and tRNA mutations
(Geraldes and King 2010) to type 2 diabetes and hypertension directly implicated
mitochondrial dysfunction in development of cardiovascular disease and
metabolic syndrome (Wallace 2005).

Taken together, there is significant

evidence that altered mitochondrial genetic expression may have a significant
role in the generation of cardiovascular disease phenotypes.

However, the

regulatory mechanisms in which mitochondria and mitochondrial genes are
expressed and regulated in disease is mostly unknown.

In contrast, the role of the kidney in long-term blood pressure regulation and
manifestation of hypertension is well known. The importance of kidney function
to modulate blood pressure has been shown by Lifton et al. (2001) demonstrating
genetic variants in important renal pathways underlie all of the Mendelian
disorders affecting blood pressure homeostasis (Inagaki, Churchill et al. 2006).
Therefore, it is postulated that altered renal expression of genes may contribute
significantly to the disease. The goal of the present study was to determine the
renal expression of mitochondrial protein-coding genes, the nuclear pathway that
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regulates their expression and the relationship between heritable hypertension in
a rat strain with localized mt-DNA from Okomoto-Aoki SHR. The “conplastic”
strain was developed by crossing a hypertensive female SHR with normotensive,
male BN rats (BN/SHR-mtSHR) (Collett, Hart et al. 2013). Hypertensive female
offspring then were phenotypically selected and crossed with founder males for
several generations.

All offspring had identical mitochondrial DNA of the

progenitor SHR, barring any mutation. The results of these studies document
significant reduced expression of renal mtRNA and nuclear encoded regulatory
elements in hypertensive male and female offspring.

The data suggest that

reduced renal mtRNA expression may elicit hypertension by decreased
OXPHOS.
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5.2 Methods and Materials

5.2.1 Animals

All experiments were carried out in accordance with the AAALAC Guide to the
Care and Use of Laboratory Animals and all protocols were previously approved
by the University of Kentucky Institutional Animal Care and Use Committee. A
“conplastic” colony using phenotypic selection was employed. The development
and phenotypic characterization have been described in detail elsewhere (Collett,
Hart et al. 2013).

The Aoki-Okamoto SHR/Brown Norway rat colony was

developed by breeding a female SHR (Charles River Labs, Wilmington, MA) with
2 different normotensive BN males (Charles River Labs, Wilmington, MA)
(BN/SHR-mtSHR). Beginning at 10 weeks of age, rats were phenotyped using tail
cuff plethysmography (Kent Scientific, Torrington, CT).

Hypertensive female

offspring were then back-crossed to the original progenitor BN males for 5
subsequent generations.

After repeated blood pressure recordings that assured consistent determination
of arterial pressure, rats not scheduled for rebreeding were euthanized with an
overdose of sodium pentobarbital (60 mg/kg i.p)., and organ tissues were rapidly
frozen and stored for later analysis.
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5.2.2 Measurement of arterial pressure.

Systolic arterial pressure (SAP) was evaluated using in parents and offspring
beginning at 10-12 weeks of age.

Phenotypes were assigned as either

normotensive (NT: SAP ≤ 124mmHg), borderline hypertensive (BHT: 125 ≤ SAP
< 150 mmHg) or hypertensive (HT: SAP ≥ 150mmHg). Arterial pressure was
derived from the average results of ≥5 measurements in each recording session.
The average blood pressures of ≥5mmHg separate recording sessions with <5%
variability were used to establish the phenotype of each animal.

Systolic

pressures were used for the determination of the specific individual phenotype
(Collett, Hart et al. 2013) .

5.2.3 RNA Extraction and RT-PCR.

Renal cortex and outer medulla homogenate, liver and left ventricular cardiac
tissue were selected from HT and NT BN/SHR-mtSHR rats (n=20 NT; n=20 HT) as
described above.

Total RNA was extracted with Trizol reagent (Invitrogen,

Carlsbad, CA) and purified using RNeasy minicolumns (Qiagen Inc., Valencia,
CA) according to the manufacturer’s protocol.

Possible genomic DNA was

digested with DNase I (Qiagen Inc., Valencia, CA). Concentration and purity of
all RNA samples was determined by the Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies, Wilmington, DE).

Extracted RNA was reverse-

transcribed into complementary DNA (cDNA) using qScript cDNA Supermix
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(Quanta Biosciences, Gaithersburg, MD) in a total volume of 20µl using a
MyCyler Thermal Cycler (Bio-Rad Laboratories, Hercules, CA).

5.2.4 Quantitative Real-Time PCR.

Quantitative Real-Time PCR was performed on a StepOnePlus Real-time PCR
system (Applied Biosystems, Foster City, CA).

Real-time quantitative PCR

amplifications were performed in triplicate on a 96-well plate.

Pre-designed

TaqMan primers and hydrolysis probes for all genes of interest were purchased
from Applied Biosystems (mt-ND1- Rn03296764_s1, mt-ND2- Rn03296765_s1,
mt-ND3-

Rn03296825_s1,

mt-ND4-

Rn03296781_s1,

mt-ND4L-

Rn03296792_s1, mt-ND5- Rn03296799_s1, mt-ND6- Rn03296815_s1, mt-CO1Rn03296721_s1, mt-CO2- Rn03296737_s1, mt-CO3- Rn03296820_s1, mt-CYBRn03296746_s1, mt-ATP6- Rn03296710_s1, mt-ATP8- Rn03296716_s1, NRF1Rn01455958_m1, NRF2a- Rn01767215_m1, NRF2b-Rn01514289_g1, Pgc1αRn00598552_m1,

Tfam-Rn00580051_m1,

Cyc1-Rn01504159_g1,

Cox6c-

Rn00820983_gH, GAPDH- Rn01775763_g1). Primers and probes were verified
and operating at similar efficiencies.

Target gene and endogenous control

amplicons were labeled with either FAM or VIC. The levels of glyceraldehyde-3phosphate dehydrogenase (GAPDH) RNA expression were measured in all
samples to normalize gene expression for sample-to-sample differences in RNA
input, RNA quality and reverse transcription efficiency.

Each sample was

analyzed in triplicate, and the expression was calculated according to the
2−ΔΔCt method (Bright and Mochly-Rosen 2005; Coble, Johnson et al. 2014).
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5.2.5 Citrate Synthase Assay.

Citrate synthase activity was determined in homogenates prepared from kidney
tissue using a citrate synthase assay kit (CS0720; Sigma-Aldrich, St. Louis,
MO). Total muscle protein was determined in triplicate by the method of Bradford
(Buchholz, Dundore et al. 1991) and the protein concentration of all samples was
equalized. Citrate synthase activity was determined based on the formation of 2nitro-5-thiobenzoic acid at a wavelength of 412 nm at 25°C on a microplate
absorbance reader (iMark; BIO RAD, Hercules, CA). In each well, 8 μl of sample
was added to a reaction medium containing 178 μl of assay buffer, 2 μl of 30
mmol/L acetyl coenzyme A, and 10 mmol/L 2-nitro-5-thiobenzoic acid. The
baseline solution absorbance was recorded, reactions were initiated by the
addition of 10 μl of oxaloacetic acid, and the change in absorbance measured
every 15 seconds for 2 minutes.

5.2.6 Cytochrome Oxidase Histochemistry.

Cytochrome oxidase (CO) activity was determined in fresh frozen sections
(20µm) in kidney, liver and heart tissue, as described previously (WhitfieldRucker and Cassone 2000).
cryostat at 20 µm.

Briefly, fresh frozen tissue was sectioned on a

Slides were immersed in 0.5% glutaraldehyde in 0.1%

phosphate buffer for 5 minutes. Slides were then incubated for 2 hours in a
diaminobenzidene (DAB)/cytochrome c solution (preceded by 5 minutes of
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sparged oxygen) at 37ºC. Slides were then postfixed in 10% formalin for 15
minutes. Finally, slides were immersed in a serious of ethanol dehydration steps:
50, 70, 90, 95, 100% ethanol (30 seconds each) and xylene (2 changes, 5
minutes each).

Slides were then coverslipped using Histomount (Life

Technologies) and dried overnight. Colorometric change was used as a direct
measurement of OXPHOS, in which darker color indicated higher metabolically
active tissue. Relative density per area was calculated using ImageJ (NIH).

5.2.7 Statistical Analysis.

Blood pressures and citrate synthase activity among animals were initially
analyzed by 1-way analysis of variance (ANOVA) followed by post-hoc
comparisons using the Bonferroni t-test. Tissue mRNA expression levels were
analyzed using Mann-Whitney U Test comparisons. The 0.05 level of probability
was utilized as the criterion of significance.

All statistical analyses were

performed using GraphPad Prism 4.0 (GraphPad Software, Inc., La Jolla, CA).
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5.3 Results

5.3.1 Evaluation of mt-gene expression

Quantitative real-time PCR was used to identify genes differentially expressed in
renal tissue from hypertensive and normotensive BN/SHR-mtSHR rats. Multiple
mtDNA encoded genes of the mitochondrial respiratory chain were significantly
reduced in renal, but not liver or cardiac tissue of HT BN/SHR-mtSHR, including
five complex I, one complex III, three complex IV and both subunits of ATP
synthase. The well-established pathway in mammalian cells for mt-transcription
initiation was evaluated using qPCR. Tfam, NRF1, NRF2a, NRF2b and Pgc-1α
were all downregulated in the kidney, but not elsewhere, of HT BN/SHR-mtSHR .

5.3.1.1 Complex I: NADH Dehydrogenase

Seven of the forty six genes that encode vital proteins for complex I of the
electron transport chain are mt-encoded. The renal mtRNA expression of five of
the seven were significantly reduced in hypertensive versus normotensive
BN/SHR-mtSHR. mt-ND1 was reduced ~3.7 fold in HT BN/SHR-mtSHR (P<0.05).
mt-ND3 was reduced ~2.6 fold in HT SHR/BN-mtSHR (P<0.01). mt-ND4 was
reduced ~10.8 fold in HT SHR/BN-mtSHR (P<0.05). mt-ND4L was reduced ~7.7
fold in HT SHR/BN-mtSHR (P<0.05).

mt-ND5 was reduced ~2.7 fold in HT

SHR/BN-mtSHR (P<0.05). mt-ND6 was reduced ~1.7 fold in HT SHR/BN-mtSHR
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(P>0.05) (Figure 5.1A). mt-ND2 was not different between the two phenotypes
(P>0.05).

5.3.1.2 Complex 3: Cytochrome bc1 Complex

One of the eleven genes that encode vital proteins for complex three of the
electron transport chain is mt-encoded. The renal mtRNA expression of mtencoded cytochrome b (mt-CYB) was significantly reduced in hypertensive
versus NT BN/SHR-mtSHR. mt-CYB was reduced ~5 fold in HT BN/SHR-mtSHR
(P<0.05) (Figure 5.1B).

5.3.1.3 Complex 4: Cytochrome C oxidase

Three of the thirteen genes that encode vital proteins for complex IV of the
electron transport chain are mt-encoded.

All three genes were significantly

reduced in hypertensive versus normotensive BN/SHR-mtSHR.

mt-CO1 was

reduced ~3.2 fold in HT BN/SHR-mtSHR (P<0.05), mt-CO2 was reduced ~3.6 fold
in HT BN/SHR-mtSHR (P<0.01), and mt-CO3 was reduced 4.1 fold in HT
BN/SHR-mtSHR (P<0.01) (Figure 5.1C).
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5.3.1.4 Complex V: ATP synthase

Two of the sixteen genes that encode vital proteins for ATP synthase of the
electron transport chain are mt-encoded. mt-ATP6 was reduced ~2.3 fold in HT
BN/SHR--mtSHR (P<0.05), while mt-ATP8 was reduced ~3.1 fold in HT BN/SHRmtSHR (P<0.05) (Figure 5.1D).

5.3.1.5 Tissue expression in Liver and Heart

Expression levels of several mt-genes were evaluated in both the liver and heart
of HT and NT BN/SHR-mtSHR as described above. mt-CYB, mt-CO2 and mtND1, mt-ATP6 were shown to be not different (P>0.05) between the HT and NT
BN/SHR-mtSHR liver or heart tissues. This is in contrast to renal tissue wherein
each of these genes exhibited reduced expression in HT vs. NT animals (Figure
5.2).

5.3.2 Evaluation of Oxidative Phosphorylation: Cytochrome Oxidase
Histochemistry

CO activity was measured densitometrically in kidney, liver and heart sections
(20µm) in NT (n=6) and HT (n=6) BN/SHR-mtSHR. CO activity was significantly
lower (p<0.05) in the kidney, but not the liver or heart in HT BN/SHR-mtSHR
(Figure 5.3).
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5.3.3 Evaluation of Trans-Regulatory Factors

The well-established pathway in mammalian cells for mt-transcription initiation
was evaluated using qPCR. Pgc1a, NRF1, NRF2a, NRF2b and Tfam were all
downregulated in the kidney, but not liver tissue, of HT compared to NT BN/SHRmtSHR (n=20). The pathway leading to reduced mitochondrial gene expression is
summarized in (Figure 5.7).

5.3.3.1 Peroxisome Proliferator-Activated Receptor Gamma Co-Activator 1-alpha
(PGC-1α)

PGC-1α regulates NRF-dependent transcription, increases expression of both
mitochondrial and nuclear encoded genes of oxidative phosphorylation and
induces mitochondrial biogenesis.

HT BN/SHR-mtSHR exhibited ~2.5 fold

reduction in PGC-1α mRNA in kidney tissue compared with NT BN/SHR-mtSHR
(P<0.05) (Figure 5.4A).

5.3.3.2 Nuclear Respiratory Factors

Nuclear respiratory factors 1 and 2 are well characterized transcriptional
activators of genes involved in assembly of the respiratory apparatus, as well as
constituents of the mtDNA transcription and replication machinery (Kelly and
Scarpulla 2004). A main factor involved in mtDNA transcription is Tfam, whose
expression is regulated by NRF1. All three NRFs were reduced in the kidney,
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but not liver of HT compared to NT BN/SHR-mtSHR.

Renal NRF1 mRNA

expression was reduced ~1.8 fold in HT BN/SHR-mtSHR compared with NT
BN/SHR-mtSHR (P<0.05) (Figure 4B). Renal NRF2a mRNA expression was
reduced ~2.3 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR
(P<0.05) (Figure 4C). Renal NRF2b mRNA expression was reduced ~1.9 fold in
HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05) (Figure 5.4D).

5.3.3.3 Mitochondrial Transcription Factor A (Tfam)

Tfam is a key activator of mammalian mitochondrial transcription. Kidney, but
not liver tissue exhibited reduced Tfam mRNA expression ~2.5 fold in HT
BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05) (Figure 5.4E).

5.3.4 Nuclear-Encoded Mitochondrial Genes: Cytochrome C-1 (Cyc1),
Cytochrome C Oxidase, Subunit Vic (Cox6c)

In order to assess the downstream pathways of the nuclear encoded regulatory
elements, nuclear-encoded mitochondrial gene expression were assessed.
There was no difference in the renal mRNA expression of CYC or Cox6c
between NT (n=10) and HT (n=10) BN/SHR-mtSHR (P>0.05) (Figure 5.5).
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5.3.5 Evaluating Mitochondrial Number: Citrate Synthase Assay

To quantify mitochondrial number, citrate synthase activity was measured in
kidney homogenates of NT (n=10) and HT (n=10) BN/SHR-mtSHR (Figure 5.6).
There was no difference between the two phenotypes (P=0.9676), indicating that
mitochondrial number was not driving the reduced transcript expression in HT
BN/SHR-mtSHR kidneys.
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5.4 Discussion

There is significant evidence that mitochondria and the mitochondrial genome
may be important in the development of hypertension (Wallace 1999; Osanai,
Tanaka et al. 2001; Schwartz, Duka et al. 2004; Taylor and Turnbull 2005; de
Cavanagh, Toblli et al. 2006; Lopez-Campistrous, Hao et al. 2008; Kumarasamy,
Gopalakrishnan et al. 2010).

Of particular interest may be the nature of

mitochondrial inheritance, being strictly maternal, and of female SHR origin. The
results of the current study provide evidence that gene expression variation in
renal mitochondrial genes encoding respiratory chain complexes is related to
hypertension in rats stemming from a SHR/BN conplastic breeding paradigm.
This breeding method provided a continuous passing of the maternal
mitochondrial genome, while mixing the inherited nuclear genome between the
maternal SHR and paternal BN with each succeeding generation. We have
reported the maintenance of arterial systolic hypertension for 6 consecutive
generations in this conplastic strain despite the reduction in maternally derived
nuclear genome (Collett, Hart et al. 2013). Results from the current study show
mitochondrial protein-coding genes critical for OXPHOS exhibited significantly
reduced expression in the kidney, but not the in the liver or heart, in HT BN/SHRmtSHR compared with NT BN/SHR-mtSHR.

Additionally, in HT BN/SHR-mtSHR,

nuclear genes involved in mitochondrial biogenesis and transcription (PGC-1α,
NRF1, NRF2a/b, Tfam), exhibited reduced expression in the kidney, but not liver,
compared with NT BN/SHR-mtSHR (Figure 5.3). Thus, kidney-specific reduction
in expression of both mitochondrial and nuclear genes critical to OXPHOS is
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associated with the manifestation of hypertension in rats with intact SHR
mitochondrial genome but minimal SHR nuclear genome.

Recently, Lee et al. (2014) postulated that increased mitochondrial activity in
proximal convoluted tubule cells of young, normotensive SHR may contribute to
the development of hypertension at adulthood. These studies show that various
parameters of mitochondrial activity were elevated in very young SHR prior to the
onset of hypertension, while mt-gene expression remained unchanged.

Our

study documents mitochondrial genes encoding proteins of each mitochondrial
subunit of mRNA were reduced in renal tissue of HT BN/SHR-mtSHR compared
with NT BN/SHR-mtSHR. It is possible that mitochondrial activity is elevated in
renal proximal tubules of very young SHR prior to the onset of hypertension. As
the development of hypertension progresses in the maturing SHR, renal
mitochondrial gene expression may then decline which in turn significantly
contributes to the further elevation of blood pressure. Ongoing and future studies
are being conducted to address this possible relationship and mechanism
specific to the SHR.

The viability of individual electron transport chain subunits and the potential for
disease has been evaluated. Altered function of complex I has been linked to
cardiovascular disease (Antonicka, Ogilvie et al. 2003; Lopez-Campistrous, Hao
et al. 2008). Lopez-Campistrous et al. (2008) revealed defects in complex I in
the brainstem of SHR, resulting in increased reactive oxygen species production,
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decreased ATP synthesis and impaired respiration in hypertension . Results
from our current study indicate reduced genetic expression of most the mt-genes
coding for Complex I, suggesting that defects in complex I function may be due
to reduced mitochondrial gene expression. Altered function of complex III, a
major site of superoxide formation and ROS production, may play an important
role in renal mitochondrial ETC dysfunction and cardiovascular disease. Similar
to these findings, Das et al. (1990) reported that the regulation of ATP synthase
is abnormal in SHR cardiac cells, as demonstrated by the inability to respond to
acute increases in energy demand compared to cells from normotensive rats .
Data from our study indicate that mt-gene expression is reduced in kidneys, a
key organ in blood pressure control. Furthermore, kidneys of hypertensive rats
had reduced CO staining, indicating reduced oxidative phosphorylation
compared with NT rats (Figure 5.3). This could have profound effects, as the
kidney has high metabolic demand, particularly in regulating salt and water
balance, and hence, arterial pressure. Taken together, the altered function of
ETC subunits derived from decreased kidney-specific mt-gene expression may
have several implications to the development of hypertension.

PGC-1α plays a central role in regulating mitochondrial content and function
within cells, because of its ability to co-activate and augment several promoters
of nuclear-encoded mitochondrial genes, as well as regulating mitochondrial
transcription via the NRF-Tfam pathway (Wu, Puigserver et al. 1999). PGC-1α
regulates

NRF-dependent

transcription,
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increases

expression

of

both

mitochondrial and nuclear encoded genes of oxidative phosphorylation and
induces mitochondrial biogenesis (Scarpulla 2002).

It has been shown that

metabolic functions are controlled by PGC-1α in a tissue specific manner in
brown fat, muscle and liver (Puigserver 2005), however kidney regulation of
PGC-1α and its effectors is unknown. Results from this study show a clearly
coordinated reduction of the kidney-specific expression of nuclear and
mitochondrial genes vital to OXPHOS coinciding with the manifestation of
hypertension (Figure 5.7). It is likely that this nuclear-mitochondrial gene down
regulation is being driven by upstream events. Although the upstream signaling
involved in the activation/reduction of PGC-1α is yet to be fully elucidated,
several pathways have been described. Briefly, the activity of PGC-1α can be
modulated by numerous post-translational events, including phosphorylation by
AMP kinase (AMPK)(Fan, Rhee et al. 2004)

and cAMP response element-

binding protein (CREB) (Fernandez-Marcos and Auwerx 2011), among others
(García-Giménez, Gimeno et al. 2011).

Mitochondrial biogenesis and transcription have been thought to be regulated by
the same nuclear-mitochondrial pathway described above (Scarpulla, Vega et al.
2012).

However, mitochondrial number between NT and HT rats were not

different as measured by citrate synthase activity (Figure 5.6). Mitochondrial
encoded gene ND2 of complex 1 was also not different between the NT and HT
phenotypes (Figure 5.1A).

Subunit ND2 has been shown to play a significant

role in the assembly and/or stability of Complex I (Antonicka, Ogilvie et al. 2003).
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Results from our current study reinforce the importance of ND2 in electron
transport chain integrity, as it was the only subunit of complex I that showed no
expression difference in kidneys between the two phenotypes. In order to further
assess the downstream pathways of the nuclear-encoded regulatory elements,
the expression of two separate nuclear-encoded mitochondrial genes were
assessed. Interestingly, other nuclear-encoded mitochondrial genes known to be
regulated by the PGC-1α-NRF-Tfam pathway were not different. Neither renal
Cytochrome C-1 (Cyc1) nor cytochrome c oxidase subunit Vic (Cox6c) were not
different between HT and NT BN/SHR-mtSHR (Figure 5.5). This phenomenon
has several implications.

First, biogenesis and transcription of mitochondrial

genes, though known to be regulated by the PGC-1α pathway, may in fact be
regulated in a more complex manner than previously thought.

Furthermore,

mitochondrial gene expression appears to be regulated in a tissue-specific
manner.

If this is the case, our data indicate that tissues of high metabolic

activity may have a critical role in the development of disease. Therefore, it is
plausible that altered OXPHOS could impact renal function, which is the
cornerstone of blood pressure regulation and development of hypertension.

One of the more interesting aspects of this study is a potential ETC dysfunction
driven by transcript differences in the kidneys, but not in other tissues, of mtgenes and the nuclear trans-factors that regulate them. Cytochrome oxidase
serves as an endogenous metabolic marker.

As shown in Figure 5.3, CO

staining was significantly reduced in the kidneys, but not liver or heart of HT
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BN/SHR-mtSHR, indicating that the kidneys of hypertensive rats had reduced
OXPHOS. Altered renal function has been well recognized as a key factor in the
development and maintenance of hypertension (Bianchi, Fox et al. 1974; Curtis,
Luke et al. 1983; Dilley, Stier et al. 1984; Guyton 1990; Cowley and Roman
1996; Ichihara, Inscho et al. 1997).

One such mechanism that may be

responsible is altered regulation of the renin-angiotensin system.

The RAS

serves as one of the most powerful regulators of blood pressure.

The

interactions among RAS and altered mitochondrial function has been advanced
recently by Benigni et al. (2009). Deletion of the Agtr1a gene resulted in the
reduced

age-related

cardio-renal

complications,

biogenesis, and increased longevity in mice.

improved

mitochondrial

Treatment with antioxidants,

mitochondrial superoxide dismutase mimetics, and AT1r blockers decreased
vascular O2- production and attenuated development of hypertension in SHR
(Park, Touyz et al. 2002),(Rodriguez-Iturbe, Zhan et al. 2003),(Shokoji,
Nishiyama et al. 2003). De Cavanagh et al. (2006) demonstrated that oxidative
stress is associated with mitochondrial dysfunction in SHR, and that this
dysfunction is attenuated with AT1r blockade with losartan .

The presence and

abundance of renal AT1r is related to the propagation of the HT phenotype in
BN/SHR-mtSHR.

We have previously shown that HT BN/SHR-mtSHR exhibit

elevated AT1r mRNA (Agtr1a) expression compared to NT BN/SHR-mtSHR, while
the renal and systemic expression of renin, angiotensinogen, and angiotensinconverting enzymes were not different (Collett, Hart et al. 2013). HT BN/SHRmtSHR exhibited elevated AT1r protein compared with NT BN/SHR-mtSHR, and this
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increase was positively correlated with elevated systolic BP (Collett, Hart et al.
2013). These data highlight a renal-specific phenomenon that appears to play a
role in the pathology of hypertension in these animals.

Another mechanism that may underlie reduced mt-gene expression is altered
activity of the sympathetic nervous system. Elevated RSNA plays an important
role in the development and maintenance of hypertension in the SHR (Judy,
Watanabe et al. 1976; 1995; Karim, Defontaine et al. 1995). Increases in RSNA
decrease urinary sodium and water excretion by increasing renal tubular water
and sodium reabsorption throughout the nephron, decrease renal blood flow and
glomerular filtration rate by constricting the renal vasculature, and increase
activity of the renin-angiotensin system by stimulating renin release from
juxtaglomerular granular cells (DiBona and Kopp 1997; Osborn, Plato et al. 1997;
DiBona 2000). Activation, or overactivation of adrenergic receptors may trigger
downstream effects, altering expression of PGC-1α through phosphorylation of
AMP kinase (AMPK)(Fan, Rhee et al. 2004), cAMP response element-binding
protein (CREB) (Fernandez-Marcos and Auwerx 2011) or others (GarcíaGiménez, Gimeno et al. 2011) to ultimately decrease mt-gene expression.

Whenever mitochondrial disturbances inhibit electron transport, electrons are
forwarded into an increased generation of ROS (Wallace 2005).

Increased

mitochondrial ROS is linked to metabolic diseases such as aging, diabetes and
hypertension (Hagen, Yowe et al. 1997; Kristal, Jackson et al. 1997; Addabbo,
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Montagnani et al. 2009). Mitochondria are a major site of oxygen consumption
and oxidative stress due to generation of ROS, where complexes I and III are the
main sites of mitochondrial superoxide formation (Votyakova and Reynolds
2001).

Recently, mitochondrial ETC dysfunction has been shown to directly

cause oxidative stress during hypertension. Chan et al. (2009) reported that
mitochondrial ROS production in the rostral ventrolateral medulla is elevated in
SHRs, and that ROS dependent inhibition of mitochondrial ETC complexes I, II
and III resulted in a feed-forward production of ROS, as well as defects in antioxidant production.

Ballinger et al. (2000) have demonstrated that

reactive

oxygen species decreased mtRNA transcripts, mitochondrial protein synthesis
and decreased cellular ATP levels. Taken together, ROS decreases OXPHOS,
and decreased OXPHOS increases ROS, both of which contribute to
hypertension (Figure 5.7). Therefore, in our studies, the reduction of renal gene
expression may lead to the development and maintenance of hypertension.

In summary, we present novel data documenting a decrease in a well-defined
nDNA-mtDNA interactive pathway resulting in decreased mtDNA transcripts of
proteins vital to OXPHOS. This coordinated reduction of nuclear-mitochondrial
OXPHOS genes and its potential role in the development of hypertension until
now was largely unknown (Figure 5.7). Though the exact mechanisms driving
this reduction in gene expression is currently not known, it is clear that reduced
mt-gene expression in the kidney coincides with the development of hypertension
in BN/SHR-mtSHR.

Using our current model, where the nuclear genome is
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increasingly BN while maintaining the SHR mitochondrial genome, in
combination with other similar models, the relevance of the specific control of
each of these genomes and how they may contribute to disease may be
revealed. Furthermore, the nuclear-mitochondrial gene expression interactions
may also be critically important in the manifestation of the progression of the
renal disease process and ultimate development of hypertension. Future studies
focused on elucidating the upstream mechanisms driving the reduced expression
and subsequent potential mitochondrial dysfunction will determine if this
phenomenon may directly lead to the development of heritable hypertension.
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Figure 5.1: Quantitative Real-Time PCR mt-genes across 4 complexes of
ETC. NT animals are in white, HT animals are in black. A: mt-ND1 was
reduced ~3.7 fold in HT BN/SHR-mtSHR (*P<0.05). mt-ND3 was reduced
~2.6 fold in HT SHR/BN-mtSHR (**P<0.01). mt-ND4 was reduced ~10.8 fold
in HT SHR/BN-mtSHR (*P<0.05). mt-ND4L was reduced ~7.7 fold in HT
SHR/BN-mtSHR (P<0.05). mt-ND5 was reduced ~2.7 fold in HT SHR/BNmtSHR (P<0.05). mt-ND6 was reduced ~1.7 fold in HT SHR/BN-mtSHR
(P>0.05). mt-ND2 was not different between the two phenotypes (P>0.05).
B: mt-CYB was reduced ~5 fold in HT BN/SHR-mtSHR (*P<0.05). C: mtCO1 was reduced ~3.2 fold in HT BN/SHR-mtSHR (*P<0.05), mt-CO2 was
reduced ~3.6 fold in HT BN/SHR-mtSHR (P<0.05), and mt-CO3 was reduced
4.1 fold in HT BN/SHR-mtSHR (P<0.05). D: mt-ATP6 was reduced ~2.3 fold
in HT BN/SHR--mtSHR (*P<0.05), while mt-ATP8 was reduced ~3.1 fold in
HT BN/SHR-mtSHR (*P<0.05).
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Figure 5.2: Quantitative Real-Time PCR of representative mt-genes of
complex I-V were evaluated in liver and heart tissue of HT and NT
BN/SHR-mtSHR. NT animals are in white, HT animals are in black. A:
mt-CYB, B: mt-CO2, C: mt-ND1, and D: ATP6 were shown to be not
different (P>0.05) between the HT and NT BN/SHR-mtSHR liver and
heart compared with kidney tissue.
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Figure 5.3: Cytochrome oxidase staining was significantly
lower in the kidney of HT vs. NT BN/SHR-mtSHR (P<0.05).
However, CO staining was not different in liver (p=0.3828) or
heart (p=0.6664) of HT vs. NT BN/SHR-mtSHR. NT are in
white, HT in black.
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Figure 5.4: Quantitative Real-Time PCR graphs of the well-established nuclearmitochondrial induction of mitochondrial gene transcription. NT animals are in
white, HT animals are in black. A. Peroxisome proliferator-activated receptor
gamma coactivator 1-alpha (PGC-1α). Renal PGC-1α mRNA expression was
reduced ~2.5 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR
(P<0.05). B. Nuclear Respiration Factor (NRF) 1. Renal NRF1 mRNA expression
was reduced ~1.8 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR
(P<0.05). C. Nuclear Respiration Factor 2A. Renal NRF2A mRNA expression was
reduced ~2.3 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR
(P<0.05). D. Nuclear Respiration Factor 2B. Renal NR2B mRNA expression was
reduced ~1.9 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR
(P<0.05). E. Mitochondrial Transcription Factor A (Tfam). Renal Tfam mRNA
expression was reduced ~2.5 fold in HT BN/SHR-mtSHR compared with NT
BN/SHR-mtSHR (P<0.05) Expression levels were not different in the liver
(P>0.05) in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR for any of the
transcription factors.
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Figure 5.5: Quantitative Real-Time PCR of nuclear-encoded
mitochondrial genes. NT animals are in white, HT animals are in black.
Neither renal A: Cytochrome C-1 (Cyc1) (P=0.3928) nor B: cytochrome
c oxidase, subunit Vic (Cox6c)(P=0.7618) were different between NT and
HT BN/SHR-mtSHR.
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Figure 5.6: Citrate synthase activity was not different in renal
tissue of NT versus HT BN/SHR-mtSHR. Mitochondrial number
was not different between the two phenotypes (P=0.9676).
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Figure 5.7: Hypothetical nuclear-mitochondrial pathway driving reduced mtDNA
transcription, ultimately leading to elevated arterial pressure and hypertension.
The pathway is clearly reduced in the kidney, but not liver of HT BN/SHR-mtSHR
compared with NT BN/SHR-mtSHR.
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CHAPTER 6
GENERAL CONCLUSIONS AND DISCUSSION

The goal of this dissertation was to determine the roles that specific humoral,
genetic and genomic mechanisms play in the manifestation and maintenance of
spontaneous hypertension. This was accomplished with two major hypotheses.
One underlying hypothesis tested was that specific aspects of the reninangiotensin system, in particular, the location and abundance of AT1 receptors
was associated with hypertension, which is supported by data presented in
Chapters 3 and 4. Renal- and hypothalamic-specific expression of AT1 receptors
was associated with hypertension in rats with decreasing SHR nuclear genome.
Chapter 4 data further support tissue-specific expression, suggesting that
elevated hypothalamic AT1r protein may be associated with an impaired ability to
sense orally ingested sodium. The second major hypothesis tested was that the
maternal inheritance of the mitochondrial genome might play a specific role in the
development of hypertension. Data presented in Chapter 2 supports a dominant
expression of the hypertensive phenotype stemming from a single SHR female
rat, despite the continual reduction of the SHR nuclear genome.

With the

dominance of the hypertensive phenotype, the role of the mitochondria,
mitochondrial gene expression and mitochondrial function were investigated.
Data presented in Chapter 5 supports an important role that the mitochondria
and the regulation of the mitochondrial genome play in the development of
hypertension.

Hypertensive BN/SHR-mtSHR exhibited significant reductions of
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mtRNA compared to NT rats of the same strain, in nearly all of the
mitochondrially protein encoded genes, and this reduction coincided with a
reduction of OXPHOS. Furthermore, data presented in Chapter 5 indicates an
important role for tissue-specific expression and function of the mitochondria,
with the reduced expression of genes critical to OXPHOS, as well as reduced
OXPHOS itself, occurring in the kidney but not liver or heart in HT BN/SHRmtSHR. However, this data also implicates an important role of the nuclear factors
that regulate mitochondrial gene expression and biogenesis, leading to a future
hypothesis that it is not mitochondrial inheritance, but something upstream of the
mitochondrion, for instance the RAS that is driving mitochondrial dysfunction,
ultimately contributing to hypertension.

Presented in this final chapter is a

discussion of how these findings relate to each other and possible future
directions to take. I postulate that Ang II binding to its type 1 receptor plays a
significant role in the renal downregulation of mitochondrial gene expression and
OXPHOS, thus contributing significantly to the development and maintenance of
hypertension in BN/SHR-mtSHR (Figure 6.1).

Data presented in this dissertation supports the important role of the kidney in the
development and maintenance of hypertension.

HT BN/SHR-mtSHR exhibited

elevated AT1 gene and protein expression in the kidneys, but not the liver or
heart compared with NT BN/SHR-mtSHR.

Transcript analyses of systemic

aspects of RAS were not different between the two phenotypes in the BN/SHRmtSHR colony. This increase in kidney AT1r expression coincided with a decrease
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in mitochondrial gene expression in HT BN/SHR-mtSHR.

HT rats exhibited a

decrease in the well-defined nDNA-mtDNA interactive pathway resulting in
decreased mtDNA transcript expression of proteins vital to OXPHOS (Figure
6.1). This coordinated reduction of nuclear-mitochondrial OXPHOS genes and
its potential relationship to the development of hypertension until now was largely
unexplored.

Though the exact mechanisms driving this reduction in gene

expression is not known, it is clear that reduced mt-gene expression in the kidney
coincides with the development of hypertension in BN/SHR-mtSHR. Furthermore,
data presented in Chapter 5 indicates that HT rats exhibited reduced OXPHOS,
as HT rats exhibited decreased cytochrome oxidase staining compared with NT
BN/SHR-mtSHR, and this decrease was observed only in the kidney. What then
does this mean in terms of the development of spontaneous hypertension? Does
reduced mitochondrial gene transcription, and ultimately reduced OXPHOS lead
to reduced renal function, which then initiates chronic elevated arterial pressure?
Data presented in Chapter 4 indicates that renal function was normal between
NT and HT BN/SHR-mtSHR.

Both NT and HT rats were in negative sodium

balance, while exhibiting similar proteinuria. Since that is the case, it may be
possible that reduced renal tubular mitochondrial function makes sodium
handling in the kidney less efficient, therefore requiring chronic pressurenatriuresis and a resetting of the renal function curve. This hypothesis seems
plausible, with a reduced ability to “sense” orally ingested NaCl, HT rats require
elevated arterial pressure to maintain sodium balance, shifting the renal-function

156

curve to the right. Hence, the HT BN/SHR-mtSHR maintain sodium balance, but
at the expense of the morbidity of hypertension.

As discussed in Chapters 1, 3 and 4, Ang II plays a pivotal role in the regulation
of blood pressure, volume, and electrolyte balance. The angiotensin II, type 1
receptor has been extensively evaluated in rodents and has subsequently
become a target as a causal factor in the development of spontaneous
hypertension. Reja et al. (2006) showed that gene expression levels of AT1r,
extracellular signal-regulated kinase 2 and phosphatidylinositol 3-kinase were
significantly higher in the PVN, RVLM and adrenal medulla in SHR compared to
normotensive WKY rats. Raizada et al. (1993) showed that AT1r mRNA was
higher in the hypothalamus and brainstem of hypertensive SHR compared to
normotensive WKY rats.

Furthermore, Gyurko et al. (1993) showed that

antisense inhibition of AT1 receptor mRNA in the brain reduces the magnitude of
hypertension in adult SHR. Data from our studies strongly supports the notion
that tissue-specific elevation of AT1 receptors may play a role in SHR-derived
hypertension. In fourth generation BN/SHR-mtSHR , where the nuclear genome of
the original SHR accounts for only ~6.2%, HT rats had significantly higher AT1r
protein expression than normotensive rats in both kidney and hypothalamic
tissue. Average SAP and tissue expression of AT1r were positively correlated,
indicating that tissue-specific expression of AT1r expression may critically impact
the development and maintenance of spontaneous hypertension. In HT and NT
BN/SHR-mtSHR rats across all generations, we saw in increase in the kidney
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expression of AT1r mRNA associated with hypertension. Increased AT1r could
potentially have drastic effects on the cardiovascular system, and subsequently,
the pathogenesis of hypertension.

Ang II’s effect in the kidney would be

exacerbated, increasing proximal tubular sodium reabsorption and decreasing
renal blood flow. In the hypothalamus, elevated AT1r expression could increase
sympathetic nervous activity and/or vasopressin secretion, subsequently
increasing vascular resistance and sodium and water retention (Scherrer 1959;
Osborn and Camara 1997; Chen and Toney 2001).

Significant evidence suggests that the RAS plays a role in altering mitochondrial
function. ACE inhibitors and ARBs reduce age-related mitochondrial dysfunction
and protect against cardiac mitochondrial dysfunction following acute ischemic
attack (DE CAVANAGH, PIOTRKOWSKI et al. 2003; Monteiro, Duarte et al.
2005; de Cavanagh, Toblli et al. 2006). Ang II can induce oxidant stress by
enhancing the generation of both NO (Pueyo, Arnal et al. 1998) and NAD(P)H
oxidase-derived superoxide (Rueckschloss, Quinn et al. 2002). Ang II can also
induce endothelial NO synthase uncoupling, i.e., switching from NO to
superoxide production (Mollnau, Wendt et al. 2002). Furthermore, Ang II has
been shown to stimulate mitochondrial reactive oxygen species (mtROS)
production. Increased mtROS has been linked to metabolic diseases such as
aging, diabetes and hypertension (Hagen, Yowe et al. 1997; Kristal, Jackson et
al. 1997; Addabbo, Montagnani et al. 2009). Mitochondria are a major site of
oxygen consumption and a major site of oxidative stress due to generation of
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ROS, where complexes I and III are the main sites of mitochondrial superoxide
formation (Votyakova and Reynolds 2001). There is increasing evidence that
hypertension is associated with an increased mitochondria-derived production of
ROS in various animal models (Doughan, Harrison et al. 2008; Dikalova,
Bikineyeva et al. 2010).

In mice, acute (24 h) and chronic (14 day) Ang II

infusion led to a decreased cardiac expression of mitochondrial electron transport
chain and Krebs cycle genes (Larkin, Frank et al. 2004), supporting previous
observations that indicated a role for Ang II and Ang II-induced ROS in the
depression of mitochondrial energy metabolism (Sanbe, Tanonaka et al. 1995;
Casademont and Miro 2002; Sorescu and Griendling 2002). In rat endothelial
cells, Ang II-induced mtROS generation activates redox-sensitive nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB), which is followed by a
stimulation of vascular cell adhesion molecule-1 expression, a cytokine involved
in atherosclerosis lesion formation (Pueyo, Gonzalez et al. 2000). Recent data
suggest that brain activation of the RAS elicits intraneuronal signaling, which
involves an increased production of mitochondrial O2·− (Case, Li et al. 2013),
modulating ion channel activity and increasing neuronal firing (Yin, Yang et al.
2010). Furthermore, overexpression of mitochondrial superoxide dismutase in
the brain effectively abolishes the central angiotensin II-induced pressor
response and decreases blood pressure in rodent models of hypertension
(Zimmerman, Lazartigues et al. 2002; Chan, Wu et al. 2009). It is clear then, that
Ang II binding to its AT1 receptor has profound effects on the mitochondria and
metabolism, and therefore this pathway should be considered a potential target

159

in the treatment and/or prevention of hypertension.

The RAS-mitochondria

connection is strongly supported by work presented in this dissertation,
demonstrating an inverse relationship between renal AT1r expression and
components of OXPHOS, despite the continual reduction of the founder SHR
female nuclear genome (Figure 6.1).

Mitochondrial membranes, proteins, and mitochondrial DNA are particularly
sensitive to oxidative damage (Yakes and Van Houten 1997; Ballinger, Patterson
et al. 2000). ROS has been shown to posttranslationally modify mitochondrial
proteins leading to their inactivation, as in the case of SOD2 and aconitase, or
alter their function as occurs with cytochrome c (Brookes, Zhang et al. 2001;
MacMillan-Crow, Cruthirds et al. 2001; Chen, Deterding et al. 2002).
Mitochondrial ETC dysfunction has been shown to be causally related to
oxidative stress during hypertension.

Chan et al. (2009) reported that

mitochondrial ROS production in the RVLM is elevated in SHRs, and that ROSdependent inhibition of mitochondrial ETC complexes I, II and III resulted in a
feed-forward production of ROS, as well as defects in anti-oxidant production.
Ballinger et al. (2000) demonstrated that the reactive oxygen species H2O2 and
peroxynitrite decreased mtRNA expression, mitochondrial protein synthesis and
decreased cellular ATP levels. It is possible that ROS, known to be involved with
the development of hypertension and mitochondrial dysfunction in SHRs, may
play a role in the development of hypertension in BN/SHR-mtSHR (Figure 6.1).
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Doughan et al. (2008) has shown that the molecular mechanisms involved in Ang
II-mediated mitochondrial dysfunction (mitochondrial H2O2 production, and
decreased mitochondrial glutathione, ADP-stimulated respiration, and decreased
membrane potential) include protein kinase C (PKC) activation. Interestingly,
and of significant importance here, AT1r and α-adrenergic receptors increase
PKC activity (Tsuchida, Liu et al. 1994; Hein and Kobilka 1995; Karim,
Defontaine et al. 1995). Ang II binding to its type 1 receptor causes the G-protein
mediated stimulation of phospholipase C and phophoinositide 3 kinase, which in
turn activates PKC.

This pathway is involved with several mechanisms

associated with the pathogenesis of hypertension, including vasoconstriction,
catecholamine release, increased renal sodium reabsorption, as well as
increased vasopressin release and salt appetite (de Gasparo, Catt et al. 2000).
Buchholz et al. (1991) demonstrated that inhibition of PKC lowers blood pressure
in SHRs. Pfaff and Vallon (2002) demonstrated that the renoprotective effect of
ACE inhibitors in diabetic rats is mediated by the inhibition of PKC-β. Identifying
the exact isozyme involved in hypertension may prove to be difficult. There are
eight known homologous PKC isozymes, which are products of seven related
genes (Mochly-Rosen, Das et al. 2012).

Nowak (2002) demonstrated that

mitochondrial dysfunction and reduced OXPHOS in renal proximal tubular cells is
mediated by PKC-α and ERK1/2. Recently, Coble et al. (2014) demonstrated a
role for central PKC-α in fluid balance by showing the role of PKC-α signaling in
the SFO in fluid intake stimulated by Ang II in the brain.

To date, several other

isoforms have been implicated in cardiovascular pathologies, such as diabetes
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(Geraldes and King 2010), heart failure (Inagaki, Churchill et al. 2006) and stroke
(Bright and Mochly-Rosen 2005). Does PKC alter PGC-1α, thereby initiating the
cascade reducing mitochondrial gene expression and OXPHOS?

Does PKC

directly, or through a second messenger, alter mitochondrial function in other
ways? One future goal will be to elucidate what role, if any, PKC isozymes play
in mitochondrial dysfunction mediated by Ang II.

I believe that data presented in this dissertation strongly supports a relationship
between decreased mitochondrial gene expression, mitochondrial function and
hypertension, and that this altered mitochondrial dynamics may be mediated, at
least in part, by Ang II binding to its AT1r. Another mechanism that may underlie
reduced mt-gene expression is altered activity of the sympathetic nervous
system. Elevated RSNA plays an important role in the development and
maintenance of hypertension in the SHR (Judy, Watanabe et al. 1976; Karim,
Defontaine et al. 1995). Increases in RSNA decrease urinary sodium and water
excretion by increasing renal tubular water and sodium reabsorption throughout
the nephron, decrease renal blood flow and glomerular filtration rate by
constricting the renal vasculature, and increase activity of the renin-angiotensin
system by stimulating renin release from juxtaglomerular granular cells (DiBona
and Kopp 1997; Osborn, Plato et al. 1997; DiBona 2000).

Activation, or

overactivation of adrenergic receptors may trigger downstream effects,
potentially altering expression of PGC-1α through, for instance phosphorylation
AMP kinase (AMPK)(Fan, Rhee et al. 2004), cAMP response element-binding
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protein (CREB (Fernandez-Marcos and Auwerx 2011) or others (GarcíaGiménez, Gimeno et al. 2011) to ultimately decrease mt-gene expression.
Adrenergic activation also increases PKC activity, which has been shown to
mediate mitochondrial dysfunction in conjunction with ERK1/2 (Nowak 2002). A
second future goal is to evaluate the relationship between the sympathetic
nervous system and mitochondrial function, as elevated RSNA is a key
component of most forms of hypertension, including primary hypertension in
humans. Evaluating RAS with RSNA could provide valuable information on how
each contribute to hypertension individually and in concert with one another.

PGC-1α plays a central role in regulating mitochondrial content and function
within cells, because of its ability to co-activate and augment several promoters
of nuclear-encoded mitochondrial genes, as well as regulating mitochondrial
transcription via the NRF-Tfam pathway (Wu, Puigserver et al. 1999). PGC-1α
regulates

NRF-dependent

transcription,

increases

expression

of

both

mitochondrial and nuclear encoded genes of oxidative phosphorylation and
induces mitochondrial biogenesis (Scarpulla 2002).

It has been shown that

metabolic functions are controlled by PGC-1α in a tissue specific manner in
brown fat, muscle and liver (Puigserver 2005), however kidney regulation of
PGC-1α and its effectors was unknown until now. Results from our studies
show a clearly coordinated-reduction of the kidney-specific expression of nuclear
and mitochondrial genes vital to OXPHOS coinciding with the manifestation of
hypertension. As mentioned above, it is likely that this nuclear-mitochondrial
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gene downregulation is being driven by upstream events. A third future goal,
though related to the other two, is to elucidate the exact mechanisms that
regulate PGC-1α, particularly in a tissue-specific manner. Understanding these
mechanisms will be critical in understanding the etiology of hypertension and
cardiovascular disease.

I have postulated thus far that reduced mitochondrial gene expression and
OXPHOS may be driving hypertension. It is possible, however, that elevated
blood pressure is driving reduced mitochondrial function. Elevated ROS can
cause reduced OXPHOS, making the mitochondria less efficient. The converse
is true as well, as less efficient OXPHOS can increase mtROS.

Oxidative

mitochondrial DNA damage may affect the synthesis of components of the
respiratory chain, which in turn can further increase ROS production, initiating a
feed-forward cycle (Figure 6.1).

Chronic over activity of renal sympathetic

nerves, elevated blood pressure and a rightward shift in the renal function curve
may ultimately drive down the expression of mitochondrial genes.

High

metabolic activity in young SHRs may drive mitochondrial gene expression down
in adulthood, coinciding with the chronic elevation of BP. This “chicken-or-theegg” type question is crucial in understanding the pathology of the disease, and
one that needs to be addressed. One way this could be accomplished is to trace
the pathogenesis of the disease in developing SHRs, while monitoring tissuespecific mitochondrial function.
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Within this dissertation, I have presented data supporting the hypotheses that the
location, genetic expression and abundance of AT1 receptors is associated with
development and maintenance of spontaneous hypertension. Both renal- and
hypothalamic-specific expression of AT1 receptors was associated with
hypertension in rats with decreasing SHR nuclear genome.

Secondly, I

presented data to support the hypothesis that the maternal inheritance of the
mitochondrial genome may play a specific role in the development of
hypertension, though mitochondrial function is most likely altered upstream of the
well-known nuclear-mitochondrial pathway, and there is significant evidence that
the RAS is involved.

Most importantly, data presented here indicates both

intrinsic and extrinsic mechanisms of the kidney, i.e. the RAS, as well as genetic
and genomic mechanisms of the kidney may be driving that spontaneous
hypertension. A major question remains: Why is there tissue-specific regulation
of mitochondrial gene expression and OXPHOS, and how is this accomplished?
Future directions will try to elucidate what exact mechanisms are driving
decreased OXPHOS, as well as further investigate the importance of tissuespecific regulation of mitochondria, and how this may be causal to the
manifestation of hypertension.
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Figure 6.1: Interactions among RAS and AT1r, reduced mitochondrial gene
expression, reduced OXPHOS in the development of hypertension. There are
several possible interactions presented above which ultimately lead to chronic
elevation of arterial pressure.

Copyright © Jason Andrieu Collett 2014
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